Loading [MathJax]/jax/output/SVG/jax.js
Review Special Issues

Toxicity associated with gadolinium-based contrast-enhanced examinations

  • This article reports known and emerging adverse health effects associated with the administration of gadolinium-based contrast agents. It focuses on the issue of the incomplete excretion of these drugs leading to the deposition of gadolinium in the tissues of the patients. The evidence of deposition is reviewed. The analysis presents gaps in our knowledge but also suggests neglected or still poorly considered parameters to possibly explain discrepancies among studies (e.g. off-label use; rate of administration; gadolinium concentration in the pharmaceutical formulation, cumulative metal toxicity). The article also presents a critical assessment of some aspects reported in the literature as well as future needs. Potential biases in the investigation and evaluation of the health/clinical implications associated with gadolinium deposition are pointed out. The analysis emphasizes that the vast majority of the clinical studies conducted up to date on gadolinium-based contrast agents were designed to assess acute toxicity and diagnostic efficacy of the agents, not to identify long-term health effects.

    Citation: Silvia Maria Lattanzio. Toxicity associated with gadolinium-based contrast-enhanced examinations[J]. AIMS Biophysics, 2021, 8(2): 198-220. doi: 10.3934/biophy.2021015

    Related Papers:

    [1] Fatao Wang, Ruizhi Yang, Yining Xie, Jing Zhao . Hopf bifurcation in a delayed reaction diffusion predator-prey model with weak Allee effect on prey and fear effect on predator. AIMS Mathematics, 2023, 8(8): 17719-17743. doi: 10.3934/math.2023905
    [2] Kwadwo Antwi-Fordjour, Rana D. Parshad, Hannah E. Thompson, Stephanie B. Westaway . Fear-driven extinction and (de)stabilization in a predator-prey model incorporating prey herd behavior and mutual interference. AIMS Mathematics, 2023, 8(2): 3353-3377. doi: 10.3934/math.2023173
    [3] Weili Kong, Yuanfu Shao . The effects of fear and delay on a predator-prey model with Crowley-Martin functional response and stage structure for predator. AIMS Mathematics, 2023, 8(12): 29260-29289. doi: 10.3934/math.20231498
    [4] Yaping Wang, Yuanfu Shao, Chuanfu Chai . Dynamics of a predator-prey model with fear effects and gestation delays. AIMS Mathematics, 2023, 8(3): 7535-7559. doi: 10.3934/math.2023378
    [5] Binfeng Xie, Na Zhang . Influence of fear effect on a Holling type III prey-predator system with the prey refuge. AIMS Mathematics, 2022, 7(2): 1811-1830. doi: 10.3934/math.2022104
    [6] Xuyang Cao, Qinglong Wang, Jie Liu . Hopf bifurcation in a predator-prey model under fuzzy parameters involving prey refuge and fear effects. AIMS Mathematics, 2024, 9(9): 23945-23970. doi: 10.3934/math.20241164
    [7] Jing Zhang, Shengmao Fu . Hopf bifurcation and Turing pattern of a diffusive Rosenzweig-MacArthur model with fear factor. AIMS Mathematics, 2024, 9(11): 32514-32551. doi: 10.3934/math.20241558
    [8] Weili Kong, Yuanfu Shao . Bifurcations of a Leslie-Gower predator-prey model with fear, strong Allee effect and hunting cooperation. AIMS Mathematics, 2024, 9(11): 31607-31635. doi: 10.3934/math.20241520
    [9] Xiaoyan Zhao, Liangru Yu, Xue-Zhi Li . Dynamics analysis of a predator-prey model incorporating fear effect in prey species. AIMS Mathematics, 2025, 10(5): 12464-12492. doi: 10.3934/math.2025563
    [10] Reshma K P, Ankit Kumar . Stability and bifurcation in a predator-prey system with effect of fear and additional food. AIMS Mathematics, 2024, 9(2): 4211-4240. doi: 10.3934/math.2024208
  • This article reports known and emerging adverse health effects associated with the administration of gadolinium-based contrast agents. It focuses on the issue of the incomplete excretion of these drugs leading to the deposition of gadolinium in the tissues of the patients. The evidence of deposition is reviewed. The analysis presents gaps in our knowledge but also suggests neglected or still poorly considered parameters to possibly explain discrepancies among studies (e.g. off-label use; rate of administration; gadolinium concentration in the pharmaceutical formulation, cumulative metal toxicity). The article also presents a critical assessment of some aspects reported in the literature as well as future needs. Potential biases in the investigation and evaluation of the health/clinical implications associated with gadolinium deposition are pointed out. The analysis emphasizes that the vast majority of the clinical studies conducted up to date on gadolinium-based contrast agents were designed to assess acute toxicity and diagnostic efficacy of the agents, not to identify long-term health effects.



    The relationship between predator and prey is the main field in natural ecology, and the mathematical models describing the interaction of two populations and the corresponding behaviors of those models are also topics which lots of scholars focus on, for example, the classic predator-prey model was first proposed by Lotka [1] and Volterra [2]. Due to different ecological and environmental factors, many species are affected by diseases [3]. Thus, eco-epidemiology is also one topic of concerns for many researchers, which includes ecology and epidemiology with the main purpose of studying how diseases spread. Chattopadhyay and Arino [4] first proposed a predator-prey model with disease in prey population as follows:

    {˙s=r(s+i)(1s+ik)bsiηγ1(s)y,˙i=bsiγ(i)yci,˙y=(εγ(i)+ηεγ1(s)d)y, (1.1)

    where s and i are the number of sound prey (also named the susceptible prey) and infected prey, respectively, y is the number of predator population, γ(i) and ηγ1(s) are the predator response functions. They mainly studied the persistence and extinction of the population, the existence and stability of the equilibrium and Hopf bifurcation occurring at the positive equilibrium of system (1.1). Many scholars studied the predator-prey models with disease and time delay based on system (1.1) [5,6,7,8,9,10,11,12,13].

    In the natural world, in order to avoid being caught by predators, prey often likes to form a herd for life. This herd can be used as a protective shield against predators, because predators cannot easily attack the prey in the herd. For the predator population, it is obviously easy to catch the prey who does not form a herd. Let M(t) be the density of the population that forms the herd at time t and occupies area A, the population density of the individuals staying outside the herd is proportional to the length of the herd at time t, that is, its length is proportional to A. Because M is distributed on a flat two-dimensional area, M is an individual at the edge of the patch. At present, many scholars have studied the population with the herd behavior [14,15,16,17,18]. Recently, Saha and Samanta [19] proposed a predator-prey system with herd behavior and disease and incorporating prey refuge,

    {dXS(T)dT=rXS(1XSK)(XSK01)(B+β1)XSXIθ1XSY1+Thθ1XS,dXI(T)dT=β1XSXI˜λ(1m)XIYδ1XI,dY(T)dT=cθ1XSY1+Thθ1XSξ˜λ(1m)XIYη1Y, (1.2)

    where XS(T) and XI(T) are the density of susceptible prey and infected prey at time T, respectively, Y(T) is the density of predator at time T. K0 is the Allee threshold of susceptible prey population in absence of predator, B is the susceptible prey feels the population pressure of both susceptible and infected prey, (1m)XI(m[0,1)) is the number of infected prey that can be caught by predator. The authors obtained some dynamical behaviors, such as the boundedness and positivity of the solution, the local stability of the equilibrium.

    In addition, in the biological system, the fear effect is a universal phenomenon. Almost every creature can feel the crisis of being captured for prey and make a difference. For example, when the prey feel the risk of predation, they may abandon their previous high-risk predation habits, and re-choose a relatively low-risk predation habit, which deplete the energy of the prey[20]. And more and more scholars have done a lot of research on the fear effect between predator and prey [21,22,23,24,25,26]. Furthermore, due to the inherent fear of prey on predators, we need to take certain protection measures for the prey species to prevent all prey from being caught by the predators. Recently, some scholars have studied the predator-prey model with prey refuge, and showed that the use of refuge has a positive effect on the prey [27,28,29,30,31,32]. For example, Zhang et al. [30] studied a predator-prey model with fear effect and incorporating prey refuge

    {dxdt=αx1+Kybx2β(1m)xy1+a(1m)x,dydt=γy+cβ(1m)xy1+a(1m)x. (1.3)

    Where x and y are the density of prey and predator, respectively, K is the level of fear. (1m)x(m[0,1)) is the number of prey that can be caught by predator. They found that the fear effect can reduce the population density of predators and change stability of system by eliminating the existence of periodic solutions.

    However, some behaviors of species do not appear immediately in natural ecology, that is, there is a time delay [33,34,35,36]. Delay differential equations can reflect reality more truly and its dynamic behavior is more complicated. It is very suitable for scholars to combine time delay with stage structure, disease and other factors to study the influence of time delay [37,38,39,40]. Furthermore, the functional response of predators to prey density is essential in predator-prey system, and it can enrich the dynamics of predator-prey systems. In ecology, many factors could affect functional responses, such as prey escape ability, predator hunting ability and the structure of the prey habitat [41]. Generally, functional responses can be divided into the following types: prey-dependent (such as Holling I-III [42]) and predator-dependent (such as Beddington-DeAngelis [43], Crowley-Martin [44]). Recently, more and more scholars have studied predator-prey system with functional response functions and time delays [31,39,45].

    We assume that the number of susceptible prey is proportional to the number of existing susceptible prey, and the number of infected prey is proportional to the number of existing infected prey. Similarly, the number of predator is directly proportional to the number of existing predator. Motivated by the literatures [4,19,30], we will take fear effect, herd behavior, disease, Holling type II functional response, time delay and refuge for prey into model (1.2) as follows

    {dXS(t)dt=rXS(tτ)1+k2Y(tτ)(b+β)XSXIα(1m1)XSY1+k1(1m1)XSd1XS,dXI(t)dt=βXSXIδ(1m)XIYd2XI,dY(t)dt=cα(1m1)XSY1+k1(1m1)XSξδ(1m)XIYd3Y, (1.4)

    with the initial conditions

    XS(θ)=ϕ1(θ)>0,XI(θ)=ϕ2(θ)>0,Y(θ)=ϕ3(θ)>0,θ[τ,0),ϕi(0)>0,i=1,2,3, (1.5)

    where XS(t) and XI(t) are the density of susceptible prey and infected prey at time t, respectively, Y(t) is the density of predator at time t. r is the intrinsic growth rate of susceptible prey, k2 is the level of fear of predators by the susceptible prey, b is the susceptible prey feels the population pressure of both susceptible and infected prey, β is the infection rate from susceptible prey to infected prey. α is the predator's capture rate for susceptible prey, k1 is the half-saturation constant, (1m1)XS(m1[0,1)) is the number of susceptible prey that can be caught by predator. δ is the predator's capture rate for infected prey, (1m)XI(m[0,1)) is the number of infected prey that can be caught by predator. c and ξ are the conversion rates of the predator, d1,d2 and d3 are the natural death rates of susceptible prey, infected prey and predator, respectively. τ is the reaction time of the susceptible prey when they feel the predation crisis. All parameters are positive constants.

    The organization of this article is as follows: In Section 2, the positiveness and boundedness of system (1.4) without time delay, the basic reproduction number R0 and the existence and stability of the equilibria are given. In Section 3, the stability of the positive equilibrium and the existence of Hopf bifurcation are studied, respectively. In Section 4, we give the global stability of the disease-free equilibrium and the positive equilibrium. The Lyapunov exponent of system (2.1) is calculated in Section 5. In Section 6, the direction and the stability of Hopf bifurcation are studied based on the center manifold theorem and the normal form theory. To support our theoretical results, some numerical simulations are given in last section.

    Firstly, we give system (1.4) without time delay as follow:

    {dXS(t)dt=rXS1+k2Y(b+β)XSXIα(1m1)XSY1+k1(1m1)XSd1XS,dXI(t)dt=βXSXIδ(1m)XIYd2XI,dY(t)dt=cα(1m1)XSY1+k1(1m1)XSξδ(1m)XIYd3Y, (2.1)

    with the initial conditions

    XS(0)>0,XI(0)>0,Y(0)>0.

    In natural ecology, positiveness means that the population can survive, and boundedness means that the resources of the population are limited. Therefore, we will discuss the positiveness and boundedness of system (2.1).

    Lemma 2.1. All solutions of system (2.1) that start in R3+ remain positive for all time.

    Proof. Because system (2.1) is continuous and satisfy the local Lipschitz condition on the continuous function space C, the solution (XS(t),XI(t),Y(t)) of system (2.1) exists and is unique with the positive initial conditions (XS(0),XI(0),Y(0)) on [0,ζ), where 0<ζ+. From the first equation of system (2.1), we can get

    dXS(t)dt=(r1+k2Y(b+β)XIα(1m1)YXS+k1(1m1)XSd1)XS,

    that is:

    XS(t)=XS(0)exp{t0[r1+k2Y(s)(b+β)XI(s)α(1m1)Y(s)XS(s)+k1(1m1)XS(s)d1]ds}>0,forXS(0)>0.

    Similarly, we have that

    XI(t)=XI(0)exp{t0[βXS(s)δ(1m)Y(s)d2]ds}>0,forXI(0)>0.Y(t)=Y(0)exp{t0[cα(1m1)XS(s)XS(s)+k1(1m1)XS(s)ξδ(1m)XI(s)d3]ds}>0,forY(0)>0.

    Lemma 2.2. All solutions of system (2.1) which in Ω are uniformly bounded.

    Proof. Let XS(t),XI(t),Y(t) be the solution of system (2.1) under the initial condition.

    Case I: If XS(0)1, then XS(t)1.

    Assuming that it is not true, then t1 and t2 such that XS(t1)=1 and XS(t)>1, t(t1,t2). So

    XS(t)=XS(0)exp{t0ϕ(XS(s),XI(s),Y(s))ds},t(t1,t2),

    where ϕ(XS(s),XI(s),Y(s))=r1+k2Y(s)(b+β)XI(s)α(1m1)Y(s)XS(s)+k1(1m1)XS(s)d1.

    Therefore

    XS(t)=XS(0)exp{t10ϕ(XS(s),XI(s),Y(s))ds+tt1ϕ(XS(s),XI(s),Y(s))ds}=XS(t1)exp{tt1ϕ(XS(s),XI(s),Y(s))ds}.

    Since XS(t1)=1, ϕ(XS(s),XI(s),Y(s))<0. Hence, XS(t)<1, which is a contradiction.

    Case II: If XS(0)>1, then limtsupXS(t)1.

    Suppose it is not true, then XS(t)>1, t>0 and ϕ(XS(s),XI(s),Y(s))<0. Therefore, we have

    XS(t)=XS(0)exp{t0ϕ(XS(s),XI(s),Y(s))ds}<XS(0).

    Next, we construct a function W(t) as follows:

    W(t)=PXS(t)+QXI(t)+RY(t), (2.2)

    where P(b+β)=Qβ,P=cR. By differentiating (2.2) with respect to t, we get

    dWdt=PdXSdt+QdXIdt+RdYdt=P(rXS1+k2Yd1XS)+Q[δ(1m)XIYd2XI]+R[ξδ(1m)XIYd3Y]PrXS1+k2YPd1XSQd2XIRd3YPrXSPd1XSQd2XIRd3Y.

    Let E=rXS, then E attains its maximum value at Emax=1P. Hence

    dWdt1κW,κ=min{d1,d2,d3},

    that is

    W(t)1κ+W(XS(0),XI(0),Y(0))eκt.

    That is limtW(t)1κ. So, all solutions of system (2.1) will enter into the region:

    Ω={(XS,XI,Y):0XS(t)1,0W(t)1κ+ϵ,ϵ>0}.

    In this subsection, we will discuss the existence and local stability of equilibria of system (2.1). By calculations, system (2.1) has four equilibria as follows.

    Theorem 2.1. The trivial equilibrium E0 of system (2.1) is unstable.

    Proof. In order to analyze the local stability of the trivial equilibrium E0(0,0,0), we redefine the variables XA(t) as XS(t)=X2A(t). Then system (2.1) transforms to the following form

    {dXAdt=12[rXA1+k2Y(b+β)XAXIα(1m1)Y1+k1(1m1)XAd1XA],dXIdt=βX2AXIδ(1m)XIYd2XI,dYdt=cα(1m1)XAY1+k1(1m1)XAξδ(1m)XIYd3Y. (2.3)

    The characteristic equation of system (2.3) at the trivial equilibrium E0 is

    [λ12(rd1)](λ+d2)(λ+d3)=0. (2.4)

    Therefore, Eq (2.4) has three eigenvalues are λ1=12(rd1),λ2=d2,λ3=d3.

    Thus, when rd1<0, the trivial equilibrium E0 is locally asymptotically stable. But the trivial equilibrium E0 is unstable when rd1>0. In fact, if rd1<0, then susceptible prey population not exist, thus E0 always unstable.

    The boundary predator-free equilibrium ˜E1(˜XS,˜XI,0) exists if r>d1, here ˜XS=d2β, ˜XI=rd1b+β. Now we prove the stability of the boundary predator-free equilibrium ˜E1.

    Theorem 2.2. The boundary predator-free equilibrium ˜E1 of system (2.1) is unstable.

    Proof. The Jacobian matrix of system (2.1) is as follows:

    J=(A11A12A13A21A22A23A31A32A33), (2.5)

    where

    A11=r1+k2Y(b+β)XId1α(1m1)Y2XS[1+k1(1m1)XS]2,A12=(b+β)XS,A13=α(1m1)XS1+k1(1m1)XSrk2XS(1+k2Y)2,A21=βXI,A22=βXSδ(1m)Yd2,A23=δ(1m)XI,A31=cα(1m1)Y2XS[1+k1(1m1)XS]2,A32=ξδ(1m)Y,A33=cα(1m1)XS1+k1(1m1)XSξδ(1m)XId3.

    The characteristic equation of system (2.1) at the boundary predator-free equilibrium ˜E1 is

    (λ˜A33)(λ2˜A12˜A21)=0. (2.6)

    Where ˜A12=(b+β)d2β, ˜A21=β(rd1)b+β, ˜A33=cα(1m1)d2d2β+k1(1m1)d2ξδ(1m)(rd1)b+βd3.

    Therefore, the first eigenvalue of Eq (2.6) is λ1=˜A33, and the other two eigenvalues are determined by the following equation

    λ2˜A12˜A21=0.

    Thus, the boundary predator-free equilibrium ˜E1 is locally asymptotically stable if ˜A12˜A21>0 (rd1<0) holds along with cα(1m1)d2d2β+k1(1m1)d2<ξδ(1m)(rd1)b+β+d3, but ˜E1 is unstable if ˜A12˜A21>0 does not hold. In fact, if rd1<0, then susceptible prey does not exist, thus ˜E1 is unstable.

    We can obtain the disease-free equilibrium ¯E2(¯XS,0,¯Y), here ¯XS=d23(cαk1d3)2(1m1)2. Further ¯Y satisfies the following equation:

    A1¯Y2+A2¯Y+A3=0, (2.7)

    where A1=k2α(1m1),A2={α(1m1)+k2d1[¯XS+k1(1m1)¯XS]}, A3=(rd1)[¯XS+k1(1m1)¯XS]. Let Δ=A224A1A3.

    Theorem 2.3. The disease-free equilibria of system (2.1) are as follows.

    (i) if A3>0, then system (2.1) has two disease-free equilibria ¯E21(¯XS,0,¯Y1) and ¯E22(¯XS,0,¯Y2), here ¯Y1=ΔA22A1,¯Y2=ΔA22A1.

    (ii) if Δ>0, A3<0, then system (2.1) has one disease-free equilibrium ¯E21(¯XS,0,¯Y1), here ¯Y1=ΔA22A1. \label{Theorem2.2.4}

    In addition, the basic reproduction number is given by R0=β¯XSd2. The R0 mainly represents the number of new infective generated from a single infected individual [46]. If R0<1, then the disease dies out from the system, but it remains the endemic in the host population if R0>1. Now we prove the stability of the disease-free equilibrium ¯E21(¯XS,0,¯Y1), and can use the similar methods to obtain the local stability of other disease-free equilibria.

    Theorem 2.4. The disease-free equilibrium ¯E21 is locally asymptotically stable if (H1) and (H2) hold along with β¯XSδ(1m)¯Yd2<0, but ¯E21 is unstable if (H1) and (H2) does not hold.

    Proof. The characteristic equation of system (2.1) at the disease-free equilibrium ¯E21 is

    (λJ22)[λ2(J11+J33)λ+J11J33J13J31]=0, (2.8)

    where

    J11=r1+k2¯Yd1α(1m1)¯Y2¯XS[1+k1(1m1)¯XS]2,J13=α(1m1)¯XS1+k1(1m1)¯XSrk2¯XS(1+k2¯Y)2,J22=β¯XSδ(1m)¯Yd2,J31=cα(1m1)¯Y2¯XS[1+k1(1m1)¯XS]2,J33=cα(1m1)¯XS1+k1(1m1)¯XSd3.

    Therefore, the first eigenvalue of Eq (2.8) is λ1=J22=β¯XSδ(1m)¯Yd2, and the other two eigenvalues are determined by the following equation

    λ2(J11+J33)λ+J11J33J13J31=0. (2.9)

    All eigenvalues of Eq (2.9) have negative real parts if

    (H1): r1+k2¯Y<d1+(1m1)2(cαd3k1)3¯Y2d3c2α,

    (H2): cα(1m1)¯Y2¯XS[1+k1(1m1)¯XS]2(d3crk2¯XS(1+k2¯Y)2)<0

    holds. Thus the disease-free equilibrium ¯E21 is locally asymptotically stable if assumptions (H1) and (H2) hold along with β¯XSδ(1m)¯Yd2<0, but ¯E21 is unstable if assumptions (H1) and (H2) does not hold.

    Theorem 2.5. The positive equilibrium E(XS,XI,Y) of system (2.1) exists if the assumption (H3) is true.

    Proof. We assume that E(XS,XI,Y) is a positive equilibrium of system (2.1), then XS,XI and Y satisfy the following equations

    {r1+k2Y(b+β)XIα(1m1)YXS+k1(1m1)XSd1=0,βXSδ(1m)Yd2=0,cα(1m1)XSXS+k1(1m1)XSξδ(1m)XId3=0. (2.10)

    According to Eq (2.10), we can obtain that XI=1ξδ(1m)[cα(1m1)XSXS+k1(1m1)XSd3],Y=βXSd2δ(1m), and XS(s=XS) is the positive root of the equation:

    Z1s4+Z2s3+Z3s2+Z4s+Z5=0, (2.11)

    where

    Z1=βk2(1m1)[(b+β)(cα+k1d3)+ξβα+d1k1ξδ(1m)],Z2=βk2[(b+β)d3+d1ξδ(1m)],Z3=δ(1m1)(1m)[d1d2ξk1k2rξk1δ(1m)(cα+k1d3)(b+β)βαξd1k1ξδ(1m)]+d2(1m)[(b+β)(cαk2+k1d3)2αβξd2k2],Z4=ξδ2(1m)2(rd1)+d1ξk2d2δ(1m)+(b+β)d3[k2d2δ(1m)],Z5=ξd2α(1m1)[δ(1m)k2d2].

    Thus, the positive equilibrium E(XS,XI,Y) of system (2.1) exists if the assumption

    (H3):cα(1m1)XSXS+k1(1m1)XSd3>0,βXSd2>0.

    is true.

    Next, we discuss the dynamical behavior of the positive equilibrium E(XS,XI,Y) of system (2.1) with time delay.

    In this section, we discuss the local stability of the system at the positive equilibrium and the existence of Hopf bifurcation of system (1.4). For convenience, let ˉXS(t)=XS(t)XS,ˉXI(t)=XI(t)XI,ˉY(t)=Y(t)Y, then we have the following linearized system

    {ˉXS(t)=a11ˉXS(t)+a12ˉXI(t)+a13ˉY(t)+b11ˉXS(tτ)+b13ˉY(tτ),ˉXI(t)=a21ˉXS(t)+a22ˉXI(t)+a23ˉY(t),ˉY(t)=a31ˉXS(t)+a32ˉXI(t)+a33ˉY(t), (3.1)

    where

    a11=(b+β)XId1α(1m1)Y2XS[1+k1(1m1)XS]2,a12=(b+β)XS,a13=α(1m1)XS1+k1(1m1)XS,b11=r1+k2Y,b13=rk2XS(1+k2Y)2,a21=βXI,a22=βXSδ(1m)Yd2,a23=δ(1m)XI,a31=cα(1m1)Y2XS[1+k1(1m1)XS]2,a32=ξδ(1m)Y,a33=cα(1m1)XS1+k1(1m1)XSξδ(1m)XId3.

    Therefore, the characteristic equation corresponding to system (3.1) can be given

    λ3+p2λ2+p1λ+p0+(s2λ2+s1λ+s0)eλτ=0, (3.2)

    where

    p2=(a11+a22+a33),p1=a22a33+a11a33+a11a22a12a21a13a31a23a32,p0=a11a32a23+a12a21a33+a13a22a31a11a22a33a12a23a31a21a32a13,s2=b11,s1=a33b11+a22b11a13b13,s0=a32a23b11+a22a31b13a21a32b13a22a33b11.

    In order to study the distribution of the root of Eq (3.2), we will discuss it in the following cases.

    Case I: τ=0

    The Eq (3.2) is reduced to

    λ3+p12λ2+p11λ+p10=0, (3.3)

    where p12=p2+s2,p11=p1+s1,p10=p0+s0.

    So we know that all roots of Eq (3.3) have negative real parts if the following assumption

    (H4):p12>0,p10>0,p12p11>p10,

    holds. That is, the positive equilibrium E(XS,XI,Y) of system (3.1) is locally asymptotically stable if the condition (H4) is satisfied.

    Case II: τ0

    Let iω(ω>0) be a root of Eq (3.2). By separating real and imaginary parts, it follows that

    {s1ωsinωτ+(s0s2ω2)cosωτ=p2ω2p0,s1ωcosωτ(s0s2ω2)sinωτ=ω3p1ω. (3.4)

    Adding squares of Eq (3.4), we can get

    ω6+e12ω4+e11ω2+e10=0, (3.5)

    where

    e12=p222p1s22,e11=p21+2(s0s2p0p2)s21,e10=p20s20.

    Let ω2=v, then Eq (3.5) can be written as

    v3+e12v2+e11v+e10=0. (3.6)

    Denote f(v)=v3+e12v2+e11v+e10, then f(0)=e10,limv+f(v)=+, f(v)=3v2+2e12v+e11.

    After discussion about the roots of Eq (3.6) by the method in [47], there are the following conditions.

    (H5):e100,=e2123e110,

    (H6):e100,=e2123e11>0,v=e12+3>0,f1(v)0,

    (H7):e10<0.

    Then we have the following lemma.

    Lemma 3.1. For the polynomial Eq (3.6), we have the following results.

    (1) If the assumption (H5) holds, then Eq (3.6) has no positive root.

    (2) If the assumption (H6) or the assumption (H7) holds, then Eq (3.6) has at least one positive root.

    Without loss of generality, we assume that Eq (3.6) has three positive roots defined as v1,v2 and v3. Then Eq (3.5) has three positive roots ωk=vk, k=1,2,3. According to (3.4), if vk>0, the corresponding critical value of time delay is

    τ(j)k=1ωkarccos{A40ω4k+A20ω2k+A10B40ω4k+B20ω2k+B10}+2πjωk,k=1,2,3;j=0,1,2,, (3.7)

    where A40=s1p2s2,A20=p2s0+p0s2p1s1,A10=p0s0,B40=s22,B20=s212s0s2,B10=s20. Therefore, ±iωk is a pair of purely imaginary roots of Eq (3.2) with τ=τ(j)k. And let τ0=mink{1,2,3}{τ(0)k},ω=ωk0.

    Lemma 3.2. Suppose that (H8):f(ω2)0, then the following transversality condition d(Reλ)dτ|λ=iω0 holds.

    Proof. Differentiating Eq (3.2) with respect to τ, and noticing that λ is a function of τ, then we obtain

    (dλdτ)1=3λ2+2p2λ+p1λ(λ3+p2λ2+p1λ+p0)+2λs2+s1λ(s2λ2+s1λ+s0)τλ. (3.8)

    Thus, we have

    Re(dλdτ)1=Re(3λ2+2p2λ+p1λ(λ3+p2λ2+p1λ+p0))λ=iω+Re(2λs2+s1λ(s2λ2+s1λ+s0))λ=iω=3ω4+2(p222p1)ω2+p212p0p2(ω3p1ω2)+(p0p2ω2)22s22ω2+s212s0s2(s2ω2s0)2+s21ω2. (3.9)

    From Eq (3.4) and Eq (3.9),

    sign{d(Reλ)dτ}λ=iω=sign{Re(dλdτ)1}λ=iω=3(ω2)2+2e12ω2+e11s21ω2+(s0s2ω2)2=f(ω2)s21ω2+(s0s2ω2)20.

    It follows that d(Reλ)dτ|λ=iω0 and the proof is complete.

    By Lemmas 3.1-3.2 and the Hopf bifurcation theorem [48,49], we have the following results.

    Theorem 3.1. For system (1.4) with τ0, the following results are true.

    (1) If the assumption (H5) holds, then the positive equilibrium E(XS,XI,Y) is locally asymptotically stable for all τ0.

    (2) If the assumption (H6) or the assumption (H7) and (H8) hold, then the positive equilibrium E(XS,XI,Y) is locally asymptotically stable for all τ[0,τ0) and is unstable for τ>τ0. Furthermore, system (1.4) undergoes a Hopf bifurcation at the positive equilibrium E(XS,XI,Y) when τ=τ0.

    Remark 3.1. The biological meaning of delay τ is the reaction time of the susceptible prey when they feel the predation crisis in our system (1.4). More detailed discussions on similar time delay can be found in [45]. According to our analysis of system (1.4), we find the minimum critical value of τ is τ0. According to Theorem 3.1, system (1.4) can keep its stability if the minimum reaction time of susceptible prey does not exceed τ0, otherwise system (1.4) will change its stability.

    In this section, we will discuss the global stability of equilibria which are locally asymptotically stable under some conditions.

    Theorem 4.1. The disease-free equilibrium ¯E2(¯XS,0,¯Y) is globally asymptotically stable if the assumptions (H1), (H2) and (H9) are true, here

    (H9):1m10,1m0,(cαk1d3)(1m1)2d3

    Proof. We construct a suitable Lyapunov function

    V1(XS,XI,Y)=βb+β[XS¯XS¯XSln(XS¯XS)]+XI+[Y¯Y¯Yln(Y¯Y)]. (4.1)

    Here, V1(XS,XI,Y) is a positive definite function for all (XS,XI,Y). Then differentiating (4.1) with respect to t, we get

    dV1dt=βb+β(1¯XSXS)dXSdt+dXIdt+(1¯YY)dYdt=βb+β(1¯XSXS)[rXS1+k2Y(b+β)XSXIα(1m1)XSYXS+k1(1m1)XSd1XS]+[βXSXIδ(1m)XIYd2XI]+(1¯YY)[cα(1m1)XSXS+k1(1m1)XSξδ(1m)XId3]Y.=βb+β(XS¯XS)XS[r(XS¯XS)1+k2Yd1(XS¯XS)]βb+β(XS¯XS)[α(1m1)YXS+k1(1m1)XS]+[δ(1m)Yd2]XI+(Y¯Y)Y[cα(1m1)XS(Y¯Y)XS+k1(1m1)XSξδ(1m)XI(Y¯Y)d3(Y¯Y)]
    =βb+β[kr(1+k2Y)(1+k2¯Y)+d1](XS¯XS)2XSβb+β[α(1m1)[1+2k1(1m1)XS]¯Y2XS[XS+k1(1m1)XS][¯XS+k1(1m1)¯XS]](XS¯XS)2[[δ(1m)]3Y¯Y+d2]XI[[ξδ(1m)]3XI¯XI+d3](Y¯Y)2Y+cα(1m1)(12¯XS¯XS)[XS+k1(1m1)XS][¯XS+k1(1m1)¯XS](Y¯Y)2Y.

    Therefore, for all tT(T>0) if (H9) holds. That is, d312(cαk1d3)(1m1), then dV1dt0. Let M1 be the largest invariant set in {(XS,XI,Y)|dV1dt=0}, we obtained that dV1dt=0 if and only if XS=¯XS,XI=¯XI=0,Y=¯Y. Thus, M1={¯E2}. By the LaSalle's invariance principle [50], the disease-free equilibrium ¯E2(¯XS,0,¯Y) is globally asymptotically stable.

    Theorem 4.2. The positive equilibrium E(XS,XI,Y) is globally asymptotically stable if (H6) or (H7) and (H8), (H10) hold, here

    (H10): 1m10,1m0,12XSXS0 and XS(tτ)[1+k2Y]XS[1+k2Y(tτ)]=1.

    Proof. We construct a suitable Lyapunov function:

    V2(XS,XI,Y)=βb+β[XSXSXSln(XSXS)]+[XIXIXIln(XIXI)]+[YYYln(YY)]. (4.2)

    Then differentiating (4.2) with respect to t, we get

    dV2dt=βb+β(1XSXS)dXSdt+(1XIXI)dXIdt+(1YY)dYdt=βb+β(1XSXS)[rXS(tτ)1+k2Y(tτ)(b+β)XSXIα(1m1)XSYXS+k1(1m1)XSd1XS]+(1XIXI)[βXSXIδ(1m)XIYd2XI]+(1YY)[cα(1m1)XSY1+k1(1m1)XSξδ(1m)XIYd3Y].=βb+β(XSXS)XS[rXS1+k2Yα(1m1)XSYXS+k1(1m1)XSd1XS]+(XIXI)XI[δ(1m)XIYd2XI]+(YY)Y[cα(1m1)XSYXS+k1(1m1)XSξδ(1m)XIYd3Y].+rXS(tτ)1+k2Y(tτ)XSXSrXS(tτ)1+k2Y(tτ)rXS1+k2Y+XSXSrXS1+k2Y=βb+β(XSXS)XS[r(XSXS)1+k2Yd1(XSXS)]βb+β(XSXS)[α(1m1)YXS+k1(1m1)XS]+(XIXI)XI[δ(1m)(XIXI)Yd2(XIXI)]+(YY)Y[cα(1m1)XS(YY)1+k1(1m1)XSξδ(1m)XI(YY)d3(YY)]+rXS(tτ)1+k2Y(tτ)XSXSrXS(tτ)1+k2Y(tτ)rXS1+k2Y+XSXSrXS1+k2Y=βb+β[kr(1+k2Y)(1+k2Y)+d1](XSXS)2XSβb+β[α(1m1)[1+2k1(1m1)XS]Y2XS[XS+k1(1m1)XS][XS+k1(1m1)XS]](XSXS)2[[δ(1m)]3YY+d2](XIXI)2XI[[ξδ(1m)]3XIXI+d3](YY)2Y+[cα(1m1)(12XSXS)[XS+k1(1m1)XS][XS+k1(1m1)XS]](YY)2Y+rXS(tτ)1+k2Y(tτ)rXS(tτ)1+k2Y(tτ)XSXSrXS1+k2Y+rXS1+k2YXSXS.

    Now let

    V3=V2+rttτ{XS(s)1+k2Y(s)XS1+k2YXS1+k2YlnXS(s)[1+k2Y]XS[1+k2Y(s)]}ds. (4.3)

    Then differentiating (4.3) with respect to t, we get

    dV3dt=dV2dt+rXS1+k2YrXS(tτ)1+k2Y(tτ)rXS1+k2YlnXS[1+k2Y(tτ)]XS(tτ)[1+k2Y]=βb+β[kr(1+k2Y)(1+k2Y)+d1](XSXS)2XSβb+β[α(1m1)[1+2k1(1m1)XS]Y2XS[XS+k1(1m1)XS][XS+k1(1m1)XS]](XSXS)2[[δ(1m)]3YY+d2](XIXI)2XI[[ξδ(1m)]3XIXI+d3](YY)2Y+[cα(1m1)(12XSXS)[XS+k1(1m1)XS][XS+k1(1m1)XS]](YY)2Y+rXS1+k2YXSXSrXS(tτ)1+k2Y(tτ)XSXSrXS1+k2YlnXS[1+k2Y(tτ)]XS(tτ)[1+k2Y]. (4.4)

    Define

    dV12dt=βb+β[kr(1+k2Y)(1+k2Y)+d1](XSXS)2XSβb+β[α(1m1)[1+2k1(1m1)XS]Y2XS[XS+k1(1m1)XS][XS+k1(1m1)XS]](XSXS)2[[δ(1m)]3YY+d2](XIXI)2XI[[ξδ(1m)]3XIXI+d3](YY)2Y+[cα(1m1)(12XSXS)[XS+k1(1m1)XS][XS+k1(1m1)XS]](YY)2Y. (4.5)
    dV22dt=rXS1+k2YXSXSrXS(tτ)1+k2Y(tτ)XSXSrXS1+k2YlnXS[1+k2Y(tτ)]XS(tτ)[1+k2Y]. (4.6)

    For Eq (4.5), for all tT(T>0) and 1m10,1m0,12XSXS0, then dV12dt0. Then

    dV3dt=dV12dt+dV22dt=dV12dt(rXS1+k2Y)XSXS{XS(tτ)[1+k2Y]XS[1+k2Y(tτ)]1+XS(1+k2Y)XS(1+k2Y)lnXS[1+k2Y(tτ)]XS(tτ)[1+k2Y]}.

    Noting that XS1+k2Y=XS1+k2Y at E, we have

    dV3dt=dV12dt(rXS1+k2Y)XSXS{XS(tτ)[1+k2Y]XS[1+k2Y(tτ)]1ln[XS(tτ)[1+k2Y]XS[1+k2Y(tτ)]]}.

    When n=1 in [51], if

    XS(tτ)[1+k2Y]XS[1+k2Y(tτ)]=1, (4.7)

    then dV3dt0. Let M2 be the largest invariant set in {(XS,XI,Y)|dV3dt=0}. We obtained that dV3dt=0 if and only if XS=XS,XI=XI,Y=Y,XS(tτ)[1+k2Y]XS[1+k2Y(tτ)]=1. Thus, M2={E}. By the LaSalle's invariance principle [50], the positive equilibrium E(XS,XI,Y) is globally asymptotically stable.

    Remark 4.1. According to Eq (4.5), if 12XSXS0, then dV12dt0, here XS is the positive root of Eq (2.11). That is, X has a certain mathematical expression, which is greater than or equal to 0.5. Furthermore, if Eq (4.7) is also true, then dV3dt0, which is consistent with the numerical simulation in Section 7 (see Figure 6), thus the positive equilibrium E is globally asymptotically stable.

    In a dynamic system, the Lyapunov exponent is an important indicator to measure the dynamics of the system [52]. It indicates the average exponential rate of convergence or divergence of the system between adjacent orbits in phase space.

    Theorem 5.1. If the Lyapunov exponents are all negative, then system (2.1) is globally asymptotically stable, but if one is positive, then system (2.1) is unstable.

    Proof. The Jacobian matrix corresponding of system (2.1) is Eq (2.5), on the basis of given some parameters values, initialize the Jacobian matrix (2.5), and initialize the three Lyapunov exponents to be calculated, we define a starting time:

    t1=t+tss,I1=ws, (5.1)

    where s is the number of steps in each evolution, ts is the time step, I1 is the number of evolutions and w is the total number of cycles. In Eq (2.5), we let:

    J1=(A11A21A31),J2=(A12A22A32),J3=(A13A23A33). (5.2)

    Next, use the Schmidt orthogonalization method to orthogonalize Eq (5.2), we can obtain that

    a1=J1,a2=J2(a1,J2)(a1,a1)a1,a3=J3(a1,J3)(a1,a1)a1(a2,J3)(a2,a2)a2.

    By calculation, we make the orthogonalized matrix A=[a1,a2,a3], and assume that the matrix after orthogonalization is:

    a1=(a01a02a03),a2=(a04a05a06),a3=(a07a08a09). (5.3)

    Then take the modulus length of the three vectors as:

    mod(i)=aiai(i=1,2,3). (5.4)

    Finally, the three Lyapunov exponents of system (1.4) are given:

    Li=log|mod(i)|t1(i=1,2,3). (5.5)

    Therefore, if the Lyapunov exponents are all negative, then system (2.1) is globally asymptotically stable, but if one is positive, then system (2.1) is unstable.

    In this part, we will study the direction of Hopf bifurcation and the stability of bifurcating periodic solutions of system (1.4). The theoretical approach is the normal form theory and center manifold theorem [48]. Throughout this section, we assume that system (1.4) undergoes a Hopf bifurcation at τ=τ0.

    Without loss of generality, let μ=ττ0,μR,t=sτ,XS(sτ)=ˆXS(s),XI(sτ)=ˆXI(s),Y(sτ)=ˆY(s). We denote u1(t)=XS(t)XS,u2(t)=XI(t)XI,u3(t)=Y(t)Y, then system (1.4) can be written as a functional differential equation (FDE) in C=C([1,0],R3):

    ˙u(t)=Lμ(ut)+F(μ,ut), (6.1)

    where u(t)=(u1(t),u2(t),u3(t))TC, ut(θ)=u(t+θ)=(u1(t+θ),u2(t+θ),u3(t+θ))TC and Lμ:CR3, F:R×CR3 are given by

    Lμ(ϕ)=(τ0+μ){˜Aϕ(0)+˜Bϕ(1)}, (6.2)

    and

    F(μ,ϕ)=(τ0+μ)(F1,F2,F3)T,

    where

    ϕ(θ)=(ϕ1(θ),ϕ2(θ),ϕ3(θ))TC,
    ˜A=(a11a12a13a21a22a23a31a32a33),˜B=(b110b13000000),
    {F1=k11ϕ21(0)+k12ϕ1(0)ϕ2(0)+k13ϕ1(0)ϕ3(0)+k14ϕ23(τ),F2=k21ϕ1(0)ϕ2(0)+k22ϕ2(0)ϕ3(0),F3=k31ϕ1(0)ϕ3(0)+k32ϕ2(0)ϕ3(0).

    Here

    k11=α(1m1)[1XS+4k1(1m1)+3k21(1m1)2XS]4XS[1+k1(1m1)XS]4,k12=(b+β),k13=α(1m1)2XS[1+k1(1m1)XS]2,k14=k2r[1+k2Y(tτ)],k21=β,k22=δ(1m),k31=cα(1m1)2XS[1+k1(1m1)XS]2,k32=ξδ(1m).

    By the Riesz representation theorem [53], there exists a 3×3 matrix function η(θ,μ) for θ[1,0) such that

    Lμ(ϕ)=01dη(θ,μ)ϕ(θ),ϕC([1,0],R3). (6.3)

    In fact, we can choose

    η(θ,μ)={(τ0+μ)(˜A+˜B),θ=0(τ0+μ)˜B,θ(τ0,0)(τ0+μ)˜B,θ(1,τ0)0,θ=1 (6.4)

    for ϕC1([1,0],R3), we define

    A(μ)ϕ={dϕ(θ)dθ,1θ<001dη(μ,s)ϕ(s),θ=0

    and

    Rμ(ϕ)={0,1θ<0F(μ,ϕ).θ=0

    Then, Eq (6.1) can be rewritten as

    ˙ut=A(μ)ut+R(μ)ut. (6.5)

    For φC1([1,0],(R3)), where (R3) is the three-dimensional space of row vectors, we further define the adjoint operator A of A(0):

    Aφ(s)={dφ(s)ds,0<s101dηT(t,0)φ(t),s=0

    for ϕC1([1,0],R3) and φC1([1,0],(R3)), we define the bilinear form

    φ(s),ϕ(s)=ˉφ(0)ϕ(0)01θξ=0ˉφ(ξθ)dη(θ)ϕ(ξ)dξ, (6.6)

    where η(θ)=η(θ,0),A=A(0) and A are adjoint operators. By the discussion in Section 3, we know that ±iωτ0 are eigenvalues of A(0). Thus, they are also the eigenvalues of A.

    We suppose that q(θ)=(1,q2,q3)Teiωτ0θ is the eigenvector of A(0) corresponding to the eigenvalue iωτ0, and q(s)=D(1,q2,q3)eiωτ0s is the eigenvector of A corresponding to the eigenvalue iωτ0. By computation, we obtain

    q2=(iωa33)q3a31a32,q3=(iωa22)a31+a32a21(iωa22)(iωa33)a23,q2=(iωa11b11eiωτ0)a13q3a21,q3=a21iω+a23(iωa11b11eiωτ0)a21(a13b13eiωτ0)a23a13a21a33.

    Then, from Eq (6.6), we get

    q(s),q(θ)=ˉq(0)q(0)01θξ=0ˉqdη(θ)q(ξ)dξ=ˉD[1+ˉq2q2+ˉq3q3+τ0eiωτ0(b13q3+b11)]. (6.7)

    Therefore, we choose ˉD=[1+ˉq2q2+ˉq3q3+τ0eiωτ0(b13q3+b11)]1, such that q(s),q(θ)=1,q(s),ˉq(θ)=0.

    Next, let ut be the solution of Eq (6.5) when μ=0. We define

    z(t)=q,ut,W(t,θ)=utzqˉzˉq=ut2Rez(t)q(θ). (6.8)

    On the center manifold C0, it comes to the conclusion that

    W(t,θ)=W(z(t),ˉz(t),θ)=W20(θ)z22+W11(θ)zˉz+W02ˉz22+, (6.9)

    where z and ˉz are local coordinates for C0 in the direction of q and ˉq. Note that W is real if ut is real, we only consider real solutions. From Eq (6.8), we get

    q,W=q,utzqˉzˉq=q,utq,qzq,ˉqˉz. (6.10)

    For a solution utC0 of Eqs (6.3), (6.5), (6.6) and μ=0, we have

    ˙z(t)=q,˙u(t)=q,A(0)ut+R(0)ut=A(0)q,ut+ˉq(θ)F(0,ut):=iq0z(t)+ˉqF0(z,ˉz). (6.11)

    What's more, Eq (6.11) can be rewritten as follows,

    ˙z(t)=iωz(t)+g(z,ˉz), (6.12)

    where

    g(z,ˉz)=g20z22+g11zˉz+g02ˉz22+g21z2ˉz2+. (6.13)

    It follows from Eqs (6.8) and (6.9) that

    ut(θ)=W20(θ)z22+W11(θ)zˉz+W02(θ)ˉz22+qTeiωθz+qTeiωθˉz+. (6.14)

    By Eqs (6.13) and (6.14), we obtain the following relevant parameters, which determine the direction and stability of Hopf bifurcation:

    g20=2ˉDτ0[k11+k12q2+k13q3+k14e2iωτ0q23+ˉq2(k21q2+k22q2q3)+ˉq3(k31q3+k32q2q3)],g11=ˉDτ0{2k11+k12(ˉq2+q2)+k13(ˉq3+q3)+2k14ˉq3q3eiωτ0+ˉq2[k21(ˉq2+q2)+k22(q2ˉq3+ˉq2q3)]+ˉq3[k31(ˉq3+q3)+k32(q2ˉq3+ˉq2q3)]},g02=2ˉDτ0[k11+k12ˉq2+k13ˉq3+k14ˉq23e2iωτ0+ˉq2(k21ˉq2+k22ˉq2ˉq3)+ˉq3(k31ˉq3+k32ˉq2ˉq3)],g21=2ˉDτ0{k11(12W(1)20(0)+W(1)11(0)+12W(1)20(0)+W(1)11(0))+k12(12W(1)20(0)ˉq2+W(1)11(0)q2+12W(2)20(0)+W(2)11(0))+k13(12W(1)20(0)ˉq3+W(1)11(0)q3+12W(3)20(0)+W(3)11(0))+k14[eiωτ0(12W(3)20(τ)ˉq3+W(3)11(τ)q3+12W(3)20(τ)ˉq3+W(3)11(τ)q3)]+ˉq2[k21(12W(1)20(0)ˉq2+W(1)11(0)q2+12W(2)20(0)+W(2)11(0))+k22(12W(2)20(0)ˉq3+W(2)11(0)q3+12W(3)20(0)ˉq2+W(3)11(0)q2)]+ˉq3[k31(12W(1)20(0)ˉq3+W(1)11(0)q3+12W(3)20(0)+W(3)11(0))+k32(12W(2)20(0)ˉq3+W(2)11(0)q3+12W(3)20(0)ˉq2+W(3)11(0)q2)]},

    and

    W20(θ)=ig20ωτ0q(0)eiωτ0θ+iˉg023ωτ0ˉq(0)eiωτ0θ+E1e2iωτ0θ,W11(θ)=ig11ωτ0q(0)eiωτ0θ+iˉg11ωτ0ˉq(0)eiωτ0θ+E2, (6.15)

    where E1=(E(1)1,E(2)1,E(3)1)TR3 and E2=(E(1)2,E(2)2,E(3)2)TR3 are also constant vectors and can be determined by the following equations, respectively,

    (2iωa11b11e2iωτ0a12a13b13e2iωτ0a212iωa22a23a31a322iωa33)E1=2(H1H2H3), (6.16)
    (a11b11a12a13b13a21a22a23a31a32a33)E2=(P1P2P3), (6.17)

    where

    H1=k11+k12q2+k13q3+k14e2iωτ0q23,H2=k21q2+k22q2q3,H3=k31q3+k32q2q3,P1=2k11+k12(ˉq2+q2)+k13(ˉq3+q3)+2k14ˉq3q3eiωτ0,P2=k21(ˉq2+q2)+k22(q2ˉq3+ˉq2q3),P3=k31(ˉq3+q3)+k32(q2ˉq3+ˉq2q3).

    Therefore, we can calculate g21 and the following values:

    C1(0)=i2ωτ0(g20g112|g11|2|g02|23)+g212,μ2=Re{C1(0)}Re{λ(τ0)},β2=2Re{C1(0)},T2=Im{C1(0)}+μ2Im{λ(τ0)}ωτ0, (6.18)

    which determine the properties of bifurcating periodic solutions at τ=τ0. From the discussion above, we have the following results.

    Theorem 6.1. For system (1.4), the direction of Hopf bifurcation is determined by the sign of μ2: if μ2>0(μ2<0), then the Hopf bifurcation is supercritical (subcritical). The stability of the bifurcating periodic solutions is determined by the sign of β2: if β2<0(β2>0), then the bifurcating periodic solutions are stable (unstable). The period of the bifurcating periodic solutions is determined by the sign of T2: if T2>0(T2<0), then the bifurcating periodic solutions increase (decrease).

    In this section, we present some numerical simulations of system (1.4) and system (2.1) to support our theoretical results. First, we will conduct the sensitivity analysis of some parameters of system (2.1).

    To determine the parameters that have significant impact on output variables of system (2.1), we conduct global sensitivity analysis of some parameters, many scholars have studied the sensitivity analysis of the parameters in system [54,55]. We calculate partial rank correlation coefficients (PRCCs) between the parameters r,δ,β,m1,m and k2 from system (2.1). Nonlinear and monotone relationships are observed with the input parameters of system (2.1), which is a prerequisite for computing PRCCs. Then, a total of 1000 simulations of the model per Latin hypercube sampling (LHS) were carried out using the baseline values tabulated in Table 1. According to the parameter values in Table 1, we analyze the influence of some parameters in the system on the correlation of infected prey. By sampling these parameters for 1000 times and a scatter plot with a fixed time point of 80, we obtain the sampling results in Figure 1 and scatter plot in Figure 2. Monotonical increasing (decreasing) indicates a positive (negative) correlation of the parameter with the model output. It is known from Figure 2 that several selected parameters exhibit periodic correlation, we can know that the parameters r,β and m1 show a positive correlation with the output of system, the parameters m,k2 show a little negative correlation with the output of system, and the parameter δ has no correlation with the output of system.

    Table 1.  Ranges of variability of the considered sensitive parameters of system (2.1).
    Parameter Baseline values Minimum values Maximum values
    r 0.17025 0.1374 0.2031
    β 0.6023 0.5682 0.6364
    m1 0.1997 0.1684 0.2310
    m 0.4196 0.3883 0.4509
    δ 1.5024 1.4324 1.5724
    k2 10.0414 9.6712 10.4116

     | Show Table
    DownLoad: CSV
    Figure 1.  Sampling results of 1000 times samples for infected prey of system (2.1).
    Figure 2.  Scatter plots with different parameters of system (2.1). (a) r, (b) β, (c) m1, (d) m, (e) δ, (f) k2.

    In this subsection, we will analyze the stability of system (2.1) and assume that the initial values of system (2.1) are XS(0)=0.6,XI(0)=0.1,Y(0)=0.2. First, we choose a set of parameter values: r=0.17,k2=10,b=0.5,β=0.6,α=0.6,k1=1,d1=0.01,d2=0.9,δ=1.5,c=0.89,ξ=0.14,d3=0.2,m1=0.2,m=0.42. According to the Theorem 2.5, there is a positive equilibrium E(0.6002,0.0355,0.0971). We find that the positive equilibrium E is locally asymptotically stable under this set of parameter values, the susceptible prey, infected prey and predator population have stable dynamics behavior(see Figure 3). Furthermore, according to the discussion in Section 2, we can get R0=β¯XSd2=0.37<1(because ¯XS=0.56 from Section 2.2.3), which indicates that the disease dies out from the system.

    Figure 3.  Local asymptotic stability of the positive equilibrium E(0.6002,0.0355,0.0971) of system (2.1). (a) stable behavior of number population; (b) phase portrait.

    Next, for the given parameters, we get ω=0.1486 and τ0=1.059 when system (1.4) with time delay. According to the Theorem 3.1, we can obtain that the positive equilibrium E(0.6002,0.0355,0.0971) of the system (1.4) is locally asymptotically stable when τ=0.5<τ0=1.059, the susceptible prey, infected prey and predator population have stable dynamics behavior (see Figure 4). Then, as the value of τ gradually increases, we choose the value of τ as τ=2>τ0=1.059 and obtain that C1(0)=4.54061.7383i,μ2=5.1018>0,β2=9.0812<0,T2=2.0684<0 by Eq (6.18). Moreover, we know that system (1.4) undergoes a supercritical Hopf bifurcation when the value of τ exceeds its threshold value τ0. In addition, the bifurcating periodic solutions of system (1.4) are stable, and the period of bifurcating periodic solutions decreases. We clearly see from Figure 5 that the positive equilibrium E(0.6002,0.0355,0.0971) is destabilized through a Hopf bifurcation in τ0=1.059 and a stable limit cycle appeared in phase portrait.

    Figure 4.  When τ=0.5<τ0=1.059, the positive equilibrium E(0.6002,0.0355,0.0971) is locally asymptotically stable. (a) stable behavior of number population; (b) phase portrait.
    Figure 5.  When τ=2>τ0=1.059, Hopf bifurcation occurs at the positive equilibrium E(0.6002,0.0355,0.0971). (a) Dynamical behavior of number population; (b) Phase portrait.

    Then, we choose r=0.6,d2=0.5,δ=3, the initial conditions of the variables and other parameter values are the same as those given above. According to the Theorem 4.2, system (1.4) has a positive equilibrium E(0.9023,0.1255,0.1943). By numerical simulations, we find that the positive equilibrium E is global asymptotically stable under this set of parameter values (see Figure 6). Figure 6(b) shows that the trajectory of the system (1.4) tends to the positive equilibrium E for different initial values at any time.

    Figure 6.  (a) Global asymptotic stability of the positive equilibrium E of system (1.4) when τ=1; (b) Phase portrait.

    Finally, we give some parameter values: t=0,ts=1×103,s=10,w=1×105, then the Lyapunov exponents have been derived numerically of system (2.1) for different species (see Figure 7 (a)). According to Theorem 5.1, all Lyapunov exponents are negative (L1=0.0871,L2=1.0740,L3=0.8451), thus system (2.1) is globally asymptotically stable. We draw the maximum Lyapunov exponent of system (1.4) for τ=2 (see Figure 7 (b)). In the figure, positive values of the maximum Lyapunov exponent indicates that system (1.4) is unstable. Figure 7 (b) corresponding to Figure 6, the value of time delay τ can also determine the global asymptotic stability of system (1.4).

    Figure 7.  Lyapunov Exponent of system, (a) system (2.1); (b) Maximum Lyapunov exponent of system (1.4) when τ=2.

    In this subsection, we will discuss how the susceptible refuge parameter m1 affects on each of the population when the positive equilibrium exists and is locally asymptotically stable. We study the influence of different parameter values of m1 on the population of prey and predator, which can be seen in Figure 8 and Figure 9.

    Figure 8.  Dynamical responses of system (2.1) with different m1[0,1). (a) susceptible prey population; (b) infected prey population; (c) predator population.
    Figure 9.  The solution curve of state variables of system (2.1) under different values of m1. (a) susceptible prey population; (b) infected prey population; (c) predator population.

    The dynamic response diagram of system (2.1) under different parameter values m1 is shown in Figure 8, which corresponds to Figure 9. Figure 9 shows that the solution curve of state variables of system (2.1) under different values of m1. It can be seen from Figure 9 that as the value of the m1 increases, the number of susceptible prey and infected prey gradually increases, which results in an immediate reduction in the number of predators, but system (2.1) is locally asymptotically stable all time. This shows that taking refuge measures has a positive effect on the prey population, but has a negative effect on the growth of the predator population. This conclusion is consistent with the laws of nature.

    In this subsection, we will discuss how the infected refuge parameter m affects on each of the population when the positive equilibrium exists and is locally asymptotically stable. We study the influence of different parameter values of m on the population of prey and predator, whose results are shown in Figure 10 and Figure 12.

    Figure 10.  Dynamical responses of system (2.1) with different m[0,1). (a) the susceptible prey; (b) the infected prey; (c) the predator.
    Figure 11.  Dynamical responses of system (2.1) with different k2[0,100]. (a) the susceptible prey; (b) the infected prey; (c) the predator.
    Figure 12.  The solution curve of state variables of system (2.1) under different values of m. (a) the susceptible prey; (b) the infected prey; (c) the predator.

    The dynamic response diagram of system (2.1) under different parameter values m is shown in Figure 10, which corresponds to Figure 12. Figure 12 shows that the solution curve of state variables of system (2.1) under different values of m. It can be obtained from Figure 12 that as the value of the m increases from 0 to 0.8, the number of susceptible prey and predator decreases, but the number of infected prey does not change significantly. This is mainly impact due to disease factors.

    In this subsection, we will discuss how the fear effect parameter k2 affects on each of the population when the positive equilibrium exists and is locally asymptotically stable. We study the influence of different parameter values of k2 on the population of prey and predator (seen Figure 11 and Figure 13).

    Figure 13.  The solution curve of state variables of system (2.1) under different values of fear of prey on predator k2. (a) susceptible prey; (b) infected prey; (c) predator.

    Figure 11 shows that the dynamic response diagram of system (2.1) corresponding to the fear effect parameter k2 in the time interval [0,100]. It can be seen that the influence of the fear effect k2 on the population is negative for prey and predator. That is, when the value of the fear parameter k2 increases from 0 to 40, the number of prey and predator population decreases (see Figure 13), but the level of fear effect k2 does not affect the stability of the system (2.1). This conclusion is consistent with the conclusions obtained from system (2.1) state response diagrams in Figure 13.

    Finally, we give the effect of the predator's catch rate δ for diseased prey on the number of species in system (see Figure 14). It can be seen from Figure 14 (a) that the number of susceptible prey gradually increase as δ increases, which indicates that the capture rate has a positive effect on the number of susceptible prey. However, we can obtain that the population of infected prey and predator first increases and then decreases when δ increases from Figure 14 (b) and Figure 14 (c). When it reached its critical value δC=28, the number of infected prey and predator begins to decrease. At this time, the number of predators tends to become extinct, because disease factors inhibit the growth of the number of predators and infected prey.

    Figure 14.  Dynamical responses of system (2.1) with different δ. (a) susceptible prey; (b) infected prey; (c) predator.

    In this paper, a predator-prey model with fear effect and disease in prey incorporating prey refuge is studied. To make such system be more realistic, the effect of delay denoting the reaction time of the susceptible prey who feels the predation crisis on the system is considered, and the herd behavior of prey is also considered. We assume that the predator's capture rate on prey population is in line with Holling-II type functional response function. According to calculation, the basic reproduction number is given that R0=0.37<1, which indicates the disease dies out from system. And system (2.1) has a trivial equilibrium E0, a boundary predator-free equilibrium ˜E1, a disease-free equilibrium ¯E2 and a unique positive equilibrium E. By discussing the distribution of the roots of the characteristic equation of system (2.1) and taking the time delay τ as bifurcation parameters, the stability of this system is discussed. If time delay τ is greater than its corresponding critical values, the Hopf bifurcation occurs at the positive equilibrium E. Next, the global stability of the equilibrium ¯E2 and E is proved. Furthermore, we discuss the direction and stability of Hopf bifurcation by using the center manifold theorem and the normal form theory. Finally, the stability and bifurcations affecting the prey and predator population are supported by numerical simulations.

    In the absence of time delay, we select m1, m, k2 and δ as the analysis parameters, and discuss the influence of these parameters on stability of system (2.1). We found that the parameter m1 has a positive effect on the increase of the prey population, and vice versa for the predator population (see Figure 8). The parameter m has a negative effect on the change of the prey population, but does not change significantly for the predator population (see Figure 10). In the literature [19], they studied that if the prey is infected with the disease, then the three species do not coexist. Our paper mainly introduces the influence of the fear effect k2 on system (2.1). For the parameter k2 of the level of fear of prey on the predator, as the level of fear increases, the number of prey and predator population decreases (see Figure 11). But the level of fear effect k2 does not affect the stability of system (2.1). The catch rate δ of predators to infected prey has a positive effect on the increase in the number of susceptible prey. The catch rate δ inhibits the increase in the number of predators and infected prey due to disease factors (see Figure 13). In addition, the stability of system (1.4) with time delay is discussed. The study shows that when τ=0.5<τ0=1.059, system (1.4) is locally asymptotically stable at the positive equilibrium E (see Figure 4), but system (1.4) is unstable when τ=2>τ0=1.059. Thus, Hopf bifurcation takes place when τ=τ0 (see Figure 5). In other words, the minimum reaction time of susceptible prey cannot exceed τ0, otherwise the stability of the system (1.4) will change. At the same time, the direction of Hopf bifurcation and the stability of periodic solutions are discussed by the center manifold theorem and normal form theory.

    In future, in order to obtain the greatest economic benefits, we will consider the effective harvest of the susceptible prey and predator. In addition, by considering the intrapsychic competition in the susceptible prey, we have the following model

    {dXS(t)dt=rXS(tτ)1+k2Y(tτ)(b+β)XSXIα(1m1)XSY1+k1(1m1)XSd1X2Sq1EXS,dXI(t)dt=βXSXIδ(1m)XIYd2XI,dY(t)dt=cα(1m1)XSY1+k1(1m1)XSξδ(1m)XIYd3Yq2EY.

    This work is supported by the National Natural Science Foundation of China (Grant Nos. 11661050 and 11861044), and the HongLiu First-class Disciplines Development Program of Lanzhou University of Technology. We also would like to thank two anonymous reviewers for their valuable comments and suggestions.

    All authors declare no conflicts of interest in this paper.



    Conflict of interest



    The authors declare no conflict of interest.

    [1] Tamburrini O, Aprile I, Falcone C, et al. (2011) Off-label use of intravascular iodinated organic and MR contrast media. Radiol Med 116: 1-14. doi: 10.1007/s11547-010-0601-5
    [2] Meloni MM, Barton S, Xu L, et al. (2017) Contrast agents for cardiovascular magnetic resonance imaging: an overview. J Mater Chem B 5: 5714-5725. doi: 10.1039/C7TB01241A
    [3] Lauffer RB (1987) Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design. Chem Rev 87: 901-927. doi: 10.1021/cr00081a003
    [4] Schörner W, Kazner E, Laniado M, et al. (1984) Magnetic resonance tomography (MRT) of intracranial tumours: Initial experience with the use of the contrast medium gadolinium-DTPA. Neurosurg Rev 7: 303-312. doi: 10.1007/BF01892910
    [5] Essig M, Anzalone N, Combs SE, et al. (2012) MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice. Am J Neuroradiol 33: 803-817. doi: 10.3174/ajnr.A2640
    [6] Anzalone N, Gerevini S, Scotti R, et al. (2009) Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine. Acta Radiol 50: 933-940. doi: 10.1080/02841850903095385
    [7] Malayeri AA, Brooks KM, Bryant LH, et al. (2016) National Institutes of health perspective on reports of gadolinium deposition in the brain. J Am Coll Radiol 13: 237-241. doi: 10.1016/j.jacr.2015.11.009
    [8] Weinmann HJ, Brasch RC, Press WR, et al. (1984) Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. Am J Roentgenol 142: 619-624. doi: 10.2214/ajr.142.3.619
    [9] Lin SP, Brown JJ (2007) MR contrast agents: Physical and pharmacologic basics. J Magn Reson Imaging 25: 884-899. doi: 10.1002/jmri.20955
    [10] Ersoy H, Rybicki FJ (2007) Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 26: 1190-1197. doi: 10.1002/jmri.21135
    [11] Bellin MF, Van Der Molen AJ (2008) Extracellular gadolinium-based contrast media: an overview. Eur J Radiol 66: 160-167. doi: 10.1016/j.ejrad.2008.01.023
    [12] Evans CH (1990)  Biochemistry of the Lanthanides New York: Plenum Press. doi: 10.1007/978-1-4684-8748-0
    [13] De León-Rodríguez LM, Martins AF, Pinho MC, et al. (2015) Basic MR relaxation mechanisms and contrast agent design. J Magn Reson Imaging 42: 545-565. doi: 10.1002/jmri.24787
    [14] Levine D, McDonald RJ, Kressel HY (2018) Gadolinium retention after contrast-enhanced MRI. JAMA 320: 1853-1854. doi: 10.1001/jama.2018.13362
    [15] Shepherd M, Lata S, Mani S, et al. (2009) Anaphylaxis to gadolinium radiocontrast: a case report and review of the literature. J La State Med Soc 161: 282-284.
    [16] Raisch DW, Garg V, Arabyat R, et al. (2014) Anaphylaxis associated with gadolinium-based contrast agents: Data from the food and drug administration's adverse event reporting system and review of case reports in the literature. Expert Opin Drug Saf 13: 15-23. doi: 10.1517/14740338.2013.832752
    [17] Franckenberg S, Berger F, Schaerli S, et al. (2018) Fatal anaphylactic reaction to intravenous gadobutrol, a gadolinium-based MRI contrast agent. Radiol Case Rep 13: 299-301. doi: 10.1016/j.radcr.2017.09.012
    [18] Jung JW, Kangand HR, Kim MH, et al. (2012) Immediate hypersensitivity reaction to gadolinium-based MR contrast media. Radiology 264: 414-422. doi: 10.1148/radiol.12112025
    [19] Morzycki A, Bhatia A, Murphy KJ (2017) Adverse reactions to contrast material: a Canadian update. Can Assoc Radiol J 68: 187-193. doi: 10.1016/j.carj.2016.05.006
    [20] Behzadi AH, Farooq Z, Newhouse JH, et al. (2018) MRI and CT contrast media extravasation a systematic review. Medicine 97: e0055. doi: 10.1097/MD.0000000000010055
    [21] Varela DC, Sepulveda P, Prieto J, et al. (2015) Extravasation of intravenous contrast media: What every radiologist should know. Rev Chil Radiol 21: 151-157. doi: 10.4067/S0717-93082015000400006
    [22] Blasco-Perrin H, Glaser B, Pienkowski M, et al. (2013) Gadolinium induced recurrent acute pancreatitis. Pancreatology 13: 88-89. doi: 10.1016/j.pan.2012.12.002
    [23] Unal O, Arslan H (1999) Cardiac arrest caused by IV gadopentetate dimeglumine. Am J Roentgenol 172: 1141. doi: 10.2214/ajr.172.4.10587169
    [24] US Food and Drug AdministrationMedical Imaging Drugs Advisory Committee Meeting, FDA briefing document: Gadolinium retention after gadolinium based contrast magnetic resonance imaging in patients with normal renal function. (2017) .
    [25] Maramattom BV, Manno EM, Wijdicks EFM, et al. (2005) Gadolinium encephalopathy in a patient with renal failure. Neurology 64: 1276-1278. doi: 10.1212/01.WNL.0000156805.45547.6E
    [26] Hui FK, Mullins M (2009) Persistence of gadolinium contrast enhancement in CSF: A possible harbinger of gadolinium neurotoxicity? Am J Neuroradiol 30: e1. doi: 10.3174/ajnr.A1205
    [27] Kim SH, Jo EJ, Kim MY, et al. (2013) Clinical value of radiocontrast media skin tests as a prescreening and diagnostic tool in hypersensitivity reactions. Ann Allergy Asthma Immunol 110: 258-262. doi: 10.1016/j.anai.2013.01.004
    [28] Shellock FG, Kanal E (1999) Safety of magnetic resonance imaging contrast agents. J Magn Res Im 10: 477-484. doi: 10.1002/(SICI)1522-2586(199909)10:3<477::AID-JMRI33>3.0.CO;2-E
    [29] Grobner T (2006) Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transpl 21: 1104-1108. doi: 10.1093/ndt/gfk062
    [30] Thomson LK, Thomson PC, Kingsmore DB, et al. (2015) Diagnosing nephrogenic systemic fibrosis in the post-FDA restriction era. J Magn Reson Imaging 41: 1268-1271. doi: 10.1002/jmri.24664
    [31] Larson KN, Gagnon AL, Darling MD, et al. (2015) Nephrogenic systemic fibrosis manifesting a decade after exposure to gadolinium. JAMA Dermatol 151: 1117-1120. doi: 10.1001/jamadermatol.2015.0976
    [32] Bernstein EJ, Schmidt-Lauber C, Kay J (2012) Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure. Best Pract Res Cl Rheumatol 26: 489-503. doi: 10.1016/j.berh.2012.07.008
    [33] Sanyal S, Marckmann P, Scherer S, et al. (2011) Multiorgan gadolinium (Gd) deposition and fibrosis ina patient with nephrogenic systemic fibrosis-an autopsy-based review. Nephrol Dial Transplant 26: 3616-3626. doi: 10.1093/ndt/gfr085
    [34] Kay J, Bazari H, Avery LL, et al. (2008) Case 6-2008: a 46-year-old woman with renal failure and stiffness of the joints and skin. New Engl J Med 358: 827-838. doi: 10.1056/NEJMcpc0708697
    [35] Bhave G, Lewis JB, Chang SS (2008) Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. J Urol 180: 830-835. doi: 10.1016/j.juro.2008.05.005
    [36] Cowper SE, Su LD, Bhawan J, et al. (2001) Nephrogenic fibrosing dermopathy. Am J Dermatopath 23: 383-393. doi: 10.1097/00000372-200110000-00001
    [37] Cowper SE, Robin HS, Steinberg SM, et al. (2000) Scleromyxedema-like cutaneous disease in renal dialysis patients. Lancet 356: 1000-1001. doi: 10.1016/S0140-6736(00)02694-5
    [38] Weigle JP, Broome DR (2008) Nephrogenic systemic fibrosis: chronic imaging findings and review of the medical literature. Skeletal Radiol 37: 457-464. doi: 10.1007/s00256-008-0464-1
    [39] Zou Z, Zhang HL, Roditi GH, et al. (2011) Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases. JACC: Cardiovasc Imag 4: 1206-1216. doi: 10.1016/j.jcmg.2011.08.013
    [40] Morris MF, Zhang Y, Zhang H, et al. (2009) Features of nephrogenic systemic fibrosis on radiology examinations. Am J Roentgenol 193: 61-69. doi: 10.2214/AJR.08.1352
    [41] Tsushima Y, Kanal E, Thomsen HS (2010) Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases. Brit J Radiol 83: 590-595. doi: 10.1259/bjr/17689538
    [42] Thomsen HS, Morcos SK, Almén T, et al. (2013) Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR contrast medium safety committee guidelines. Eur Radiol 23: 307-318. doi: 10.1007/s00330-012-2597-9
    [43] Mazhar SM, Shiehmorteza M, Kohl CA, et al. (2009) Nephrogenic systemic fibrosis in liver disease: a systematic review. J Magn Reson Imaging 30: 1313-1322. doi: 10.1002/jmri.21983
    [44] Elmholdt TR, Jørgensen B, Ramsing M, et al. (2010) Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol. NDT Plus 3: 285-287.
    [45] Kay J (2008) Gadolinium and nephrogenic systemic fibrosis: The evidence of things not seen. Clev Clin J Med 75: 112. doi: 10.3949/ccjm.75.2.112
    [46] Todd DJ, Kay J (2008) Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity. Curr Rheumatol Rep 10: 195-204. doi: 10.1007/s11926-008-0033-6
    [47] Sieber MA, Lengsfeld P, Frenzel T, et al. (2008) Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 18: 2164-2173. doi: 10.1007/s00330-008-0977-y
    [48] Semelka RC, Prybylskib JP, Ramalho M (2019) Influence of excess ligand on nephrogenic systemic fibrosis associated with nonionic, linear gadolinium-based contrast agents. Magn Res Imaging 58: 174-178. doi: 10.1016/j.mri.2018.11.015
    [49] US Food and Drug Administration FDA request boxes warning for contrast agents used to improve MRI images (2007) .Available from: http://wayback.archive-it.org/7993/20170112033008/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108919.htm.
    [50] Khawaja AZ, Cassidy DB, Al Shakarchi J, et al. (2015) Revisiting the risks of MRI with Gadolinium based contrast agents: review of literature and guidelines. Insights Imaging 6: 553-558. doi: 10.1007/s13244-015-0420-2
    [51] Canga A, Kislikova M, Martínez-Gálvez M, et al. (2014) Renal function, nephrogenic systemic fibrosis and other adverse reactions associated with gadolinium-based contrast media. Nefrologia 34: 428-438.
    [52] Martin DR, Krishnamoorthy SK, Kalb B, et al. (2010) Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging 31: 440-446. doi: 10.1002/jmri.22024
    [53] Altun E, Martin DR, Wertman R, et al. (2009) Nephrogenic systemic fibrosis: Change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy—report from two US universities. Radiology 253: 689-696. doi: 10.1148/radiol.2533090649
    [54] Xia D, Davis RL, Crawford JA, et al. (2010) Gadolinium released from MR contrast agents is deposited in brain tumors: in situ demonstration using scanning electron microscopy with energy dispersive X-ray spectroscopy. Acta Radiol 51: 1126-1136. doi: 10.3109/02841851.2010.515614
    [55] Kanda T, Ishii K, Kawaguchi H, et al. (2014) High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: Relationship with increasing cumulative dose of a gadolinium based contrast material. Radiology 270: 834-841. doi: 10.1148/radiol.13131669
    [56] McDonald RJ, McDonald JS, Kallmes DF, et al. (2015) Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 275: 772-782. doi: 10.1148/radiol.15150025
    [57] Olchowy C, Cebulski K, Łasecki M, et al. (2017) The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity-a systematic review. PLoS One 12: e0171704. doi: 10.1371/journal.pone.0171704
    [58] Pullicino R, Radon M, Biswas S, et al. (2018) A review of the current evidence on gadolinium deposition in the brain. Clin Neuroradiol 28: 159-169. doi: 10.1007/s00062-018-0678-0
    [59] Gianolio E, Gregorio ED, Aime S (2019) Chemical insights into the issues of Gd retention in the brain andother tissues upon the administration of Gd-containing MRI contrast agents. Eur J Inorg Chem 2019: 137-151. doi: 10.1002/ejic.201801220
    [60] Kanda T, Osawa M, Oba H, et al. (2015) High signal intensity in dentate nucleus on unenhanced T1-weightedMR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology 275: 803-809. doi: 10.1148/radiol.14140364
    [61] Weberling LD, Kieslich PJ, Kickingereder P, et al. (2015) Increased signal intensity in the dentate nucleus on unenhanced T1-weighted images after gadobenate dimeglumine administration. Invest Radiol 50: 743-748. doi: 10.1097/RLI.0000000000000206
    [62] Errante Y, Cirimele V, Mallio CA, et al. (2014) Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol 49: 685-690. doi: 10.1097/RLI.0000000000000072
    [63] Zhang Y, Cao Y, Shih GL, et al. (2017) Extent of signal hyperintensity on unenhanced T1-weighted brain MR images after more than 35 administrations of linear gadolinium-based contrast agents. Radiology 282: 516-525. doi: 10.1148/radiol.2016152864
    [64] Radbruch A, Weberling LD, Kieslich PJ, et al. (2015) Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 275: 783-791. doi: 10.1148/radiol.2015150337
    [65] Malhotra A, LeSar B, Wu X, et al. (2018) Progressive T1 shortening of the dentate nucleus in patients with multiple sclerosis: Result of multiple administrations of linear gadolinium contrast agents versus intrinsic disease. Am J Roentgenol 211: 1099-1105. doi: 10.2214/AJR.17.19155
    [66] Flood TF, Stence NV, Maloney JA, et al. (2017) Pediatric brain: Repeated exposure to linear gadolinium-based contrast material is associated with increased signal intensity at unenhanced T1-weighted MR imaging. Radiology 282: 222-228. doi: 10.1148/radiol.2016160356
    [67] Adin ME, Kleinberg L, Vaidya D, et al. (2015) Hyperintense dentate nuclei on T1-weighted MRI: relation to repeat gadolinium administration. Am J Neuroradiol 36: 1859-1865. doi: 10.3174/ajnr.A4378
    [68] Miller JH, Hu HH, Pokorney A, et al. (2015) MRI brain signal intensity changes of a child during the course of 35 gadolinium contrast examinations. Pediatrics 136: e1637-e1640. doi: 10.1542/peds.2015-2222
    [69] Hu HH, Pokorney A, Towbin RB, et al. (2016) Increased signal intensities in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evidence in children undergoing multiple gadolinium MRI exams. Pediatr Radiol 46: 1590-1598. doi: 10.1007/s00247-016-3646-3
    [70] Bae S, Lee H, Han K, et al. (2017) Gadolinium deposition in the brain: association with various GBCAs using a generalized additive model. Eur Radiol 27: 3353-3361. doi: 10.1007/s00330-016-4724-5
    [71] Quattrocchi CC, Mallio CA, Errante Y, et al. (2015) Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol 50: 470-472. doi: 10.1097/RLI.0000000000000154
    [72] McDonald JS, McDonald RJ, Jentoft ME, et al. (2017) Intracranial gadolinium deposition following gadodiamide-enhanced magnetic resonance imaging in pediatric patients: a case-control study. JAMA Pediatr 171: 705-707. doi: 10.1001/jamapediatrics.2017.0264
    [73] Mallio CA, Vullo GL, Messina L, et al. (2020) Increased T1 signal intensity of the anterior pituitary gland on unenhanced magnetic resonance images after chronic exposure to gadodiamide. Invest Radiol 55: 25-29. doi: 10.1097/RLI.0000000000000604
    [74] Gianolio E, Bardini P, Arena F, et al. (2017) Gadolinium retention in the rat brain: Assessment of the amounts of insoluble gadolinium-containing species and intact gadolinium complexes after repeated administration of gadolinium-based contrast agents. Radiology 285: 839-849. doi: 10.1148/radiol.2017162857
    [75] Rasschaert M, Schroeder JA, Wu TD, et al. (2018) Multimodal imaging study of gadolinium presence in rat cerebellum: differences between Gd chelates, presence in the Virchow-Robin space, association with lipofuscin, and hypotheses about distribution pathway. Invest Radiol 53: 518. doi: 10.1097/RLI.0000000000000490
    [76] Radbruch A, Richter H, Fingerhu S, et al. (2019) Gadolinium deposition in the brain in a large animal model. Comparison of linear and macrocyclic gadolinium-based contrast agents. Invest Radiol 54: 531-536. doi: 10.1097/RLI.0000000000000575
    [77] Boyken J, Frenzel T, Lohrke J, et al. (2018) Gadolinium accumulation in the deep cerebellar nuclei and globus pallidus after exposure to linear but not macrocyclic gadolinium-based contrast agents in a retrospective pig study with high similarity to clinical conditions. Invest Radiol 53: 278-285. doi: 10.1097/RLI.0000000000000440
    [78] Robert P, Violas X, Grand S, et al. (2016) Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats. Invest Radiol 51: 73-82. doi: 10.1097/RLI.0000000000000241
    [79] Strzeminska I, Factor C, Robert P, et al. (2020) Long-term evaluation of gadolinium retention in rat brain after single injection of a clinically relevant dose of gadolinium-based contrast agents. Invest Radiol 55: 138-143. doi: 10.1097/RLI.0000000000000623
    [80] Radbruch A, Haase R, Kieslich PJ, et al. (2017) No signal intensity increase in the dentate nucleus on unenhanced T1-weighted MR images after more than 20 serial injections of macrocyclic gadolinium-based contrast agents. Radiology 282: 699-707. doi: 10.1148/radiol.2016162241
    [81] Radbruch A, Haase R, Kickingereder P, et al. (2017) Pediatric brain: no increased signal intensity in the dentate nucleus on unenhanced T1-weighted MR images after consecutive exposure to a macrocyclic gadolinium-based contrast agent. Radiology 283: 828-836. doi: 10.1148/radiol.2017162980
    [82] Tibussek D, Rademacher C, Caspers J, et al. (2007) Gadolinium brain deposition after macrocyclic gadolinium administration: a pediatric case-control study. Radiology 285: 223-230. doi: 10.1148/radiol.2017161151
    [83] Schneider GK, Stroeder J, Roditi G, et al. (2017) T1 signal measurements in pediatric brain: findings after multiple exposures to gadobenate dimeglumine for imaging of non neurologic disease. Am J Neuroradiol 38: 1799-1806. doi: 10.3174/ajnr.A5270
    [84] Conte G, Preda L, Cocorocchio E, et al. (2017) Signal intensity change on unenhanced T1-weighted images in dentate nucleus and globus pallidus after multiple administrations of gadoxetate disodium: an intraindividual comparative study. Eur Radiol 27: 4372-4378. doi: 10.1007/s00330-017-4810-3
    [85] Ryu YJ, Choi YH, Cheon J, et al. (2018) Pediatric brain: Gadolinium deposition in dentate nucleus and globus pallidus on unenhanced T1-weighted images is dependent on the type of contrast agent. Invest Radiol 53: 246-255. doi: 10.1097/RLI.0000000000000436
    [86] Stanescu AL, Shaw DW, Murata N, et al. (2020) Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: pathological confirmation. Pediatr Radiol 50: 388-396. doi: 10.1007/s00247-019-04535-w
    [87] Bjørnerud A, Vatnehol SAS, Larsson C, et al. (2017) Signal enhancement of the dentate nucleus at unenhanced MR imaging after very high cumulative doses of the macrocyclic gadolinium-based contrast agent gadobutrol: an observational study. Radiology 285: 434-444. doi: 10.1148/radiol.2017170391
    [88] Splendiani A, Perri M, Marsecano C, et al. (2018) Effects of serial macrocyclic based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium related dentate nuclei signal increases in unenhanced t1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients. Radiol Med 123: 125-134. doi: 10.1007/s11547-017-0816-9
    [89] Stojanov DA, Aracki-Trenkic A, Vojinovic S, et al. (2016) Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing remitting multiple sclerosis: Correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol 26: 807-815. doi: 10.1007/s00330-015-3879-9
    [90] Tedeschi E, Palma G, Canna A, et al. (2016) In vivo dentate nucleus MRI relaxometry correlates with previous administration of gadolinium-based contrast agents. Eur Radiol 26: 4577-4584. doi: 10.1007/s00330-016-4245-2
    [91] Lattanzio SM, Imbesi F (2020) Fibromyalgia associated with repeated gadolinium contrast-enhanced MRI examinations. Radiol Case Rep 15: 534-541. doi: 10.1016/j.radcr.2020.02.002
    [92] Roberts DR, Welsh CA, LeBel DP, et al. (2017) Distribution map of gadolinium deposition within the cerebellum following GBCA administration. Neurology 88: 1206-1208. doi: 10.1212/WNL.0000000000003735
    [93] Gibby WA, Gibby KA, Gibby WA (2004) Comparison of Gd-DTPA-BMA (Omniscan) versus Gd-HPDO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol 39: 138-142. doi: 10.1097/01.rli.0000112789.57341.01
    [94] White GW, Gibby WA, Tweedle MF (2006) Comparison of Gd(DTPA-BMA)(Omniscan) versus Gd(HPDO3A)(ProHance) relative to gadolinium retention in human bone tissue by inductively coupled mass spectroscopy. Invest Radiol 41: 272-278. doi: 10.1097/01.rli.0000186569.32408.95
    [95] Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, et al. (2009) Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics 1: 479-488. doi: 10.1039/b905145g
    [96] Murata N, Gonzalez-Cuyar LF, Murata K, et al. (2016) Macrocyclic and other non–group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: Preliminary results from 9 patients with normal renal function. Invest Radiol 51: 447-53. doi: 10.1097/RLI.0000000000000252
    [97] Lord ML, Chettle DR, Gräfe JL, et al. (2018) Observed deposition of gadolinium in bone using a new noninvasive in vivo biomedical device: Results of a small pilot feasibility study. Radiology 287: 96-103. doi: 10.1148/radiol.2017171161
    [98] Turyanskaya A, Rauwol M, Pichler V, et al. (2020) Detection and imaging of gadolinium accumulation inhuman bone tissue by micro- and submicro-XRF. Sci Rep 10: 6301. doi: 10.1038/s41598-020-63325-9
    [99] Vidaud C, Bourgeois D, Meyer D (2012) Bone as target organ for metals: the case of f-elements. Chem Res Toxicol 25: 1161-1175. doi: 10.1021/tx300064m
    [100] Gräfe JL, McNeill FE (2018) Measurement of gadolinium retention: current status and review from an applied radiation physics perspective. Physiol Meas 39: 06TR01. doi: 10.1088/1361-6579/aacc16
    [101] Hasegawa M, Duncan BR, Marshall DA, et al. (2020) Human hair as a possible surrogate marker of retained tissue gadolinium. A pilot autopsy study correlating gadolinium concentrations in hair with brain and other tissues among decedents who received gadolinium-based contrast agents. Invest Radiol 55: 636-642. doi: 10.1097/RLI.0000000000000681
    [102] Saussereau E, Lacroix C, Cattaneo A, et al. (2008) Hair and fingernail gadolinium ICP-MS contents in an overdose case associated with nephrogenic systemic fibrosis. Forensic Sci Int 176: 54-57. doi: 10.1016/j.forsciint.2007.06.026
    [103]  US Food and Drug Administration, 5-18, 2015 Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-evaluating-risk-brain-deposits-repeated-use-gadolinium-based.
    [104]  EMA/625317/2017. EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans Available at: http://www.ema.europa.eu/docs/en _ GB/document _ library/ Referrals _ document/gadolinium _ contrast _ agents _ 31/ European _ Commission _ final _ decision/WC500240575.pdf.
    [105] Lancelot E, Desché P (2020) Gadolinium retention as a safety signal: experience of a manufacturer. Invest Radiol 55: 20-24. doi: 10.1097/RLI.0000000000000605
    [106]  PMDA, Revision of Precautions, Gadodiamide hydrate Meglumine gadopentetate, 2017 Available from: http://www.pmda.go.jp/files/000221377.pdf.
    [107]  PMDA, Revision of Precautions, Gadoxetate sodium, Gadoteridol, Meglumine gadoterate, Gadobutrol, 2017 Available from: http://www.pmda.go.jp/files/000221376.pdf.
    [108] Kanda T, Nakai Y, Hagiwara A, et al. (2017) Distribution and chemical forms of gadolinium in the brain: a review. Br J Radiol 90: 20170115. doi: 10.1259/bjr.20170115
    [109] Bracco Diagnostics Bayer, Guerbet GE Healthcare Important drug warning for all gadolinium-based contrast agents [dear health care provider letter] (2018) .Available from: https://www.guerbet.com/media/uh4h4kon/dhcp-letter-05-02-2018-signed.pdf.
    [110] Harvey HB, Gowda V, Cheng G (2019) Gadolinium deposition disease: a new risk management threat. J Am Coll Radiol 17: 546-550. doi: 10.1016/j.jacr.2019.11.009
    [111] Semelka RC, Commander CW, Jay M, et al. (2016) Presumed gadolinium toxicity in subjects with normal renal function a report of 4 cases. Invest Radiol 51: 661-665. doi: 10.1097/RLI.0000000000000318
    [112] Semelka RC, Ramalho M, Jay M (2016) Summary of special issue on gadolinium bioeffects and toxicity with a look to the future. Magn Reson Imaging 34: 1399-1401. doi: 10.1016/j.mri.2016.09.002
    [113] US Food and Drug AdministrationMedical Imaging Drugs Advisory Committee Meeting, FDA briefing document: Gadolinium retention after gadolinium-based contrast magnetic resonance imaging in patients with normal renal function, 27–28. (2017) .
    [114] Burke LMB, Ramalho M, AlObaidy M, et al. (2016) Self-reported gadolinium toxicity: A survey of patients with chronic symptoms. Magn Reson Imaging 34: 1078-1080. doi: 10.1016/j.mri.2016.05.005
    [115] Semelka RC, Ramalho J, Vakharia A, et al. (2016) Gadolinium deposition disease: initial description of adisease that has been around for a while: a family of disorders. Magn Res Imaging 34: 1383-1390. doi: 10.1016/j.mri.2016.07.016
    [116] Roberts DR, Lindhorst SM, Welsh CT, et al. (2016) High levels of gadolinium deposition in the skin of a patient with normal renal function. Invest Radiol 51: 280-289. doi: 10.1097/RLI.0000000000000266
    [117] Barbieri S, Schroeder C, Froehlich JM, et al. (2016) High signal intensity in dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in three patients with impaired renal function and vascular calcification. Contrast Media Mol Imaging 11: 245-250. doi: 10.1002/cmmi.1683
    [118] Swaminathan S (2016) Gadolinium toxicity: iron and ferroportin as central targets. Magnet Reson Imaging 34: 1373-1376. doi: 10.1016/j.mri.2016.08.016
    [119] Di Gregorio ED, Furlan C, Atlante S, et al. (2020) Gadolinium retention in erithrocytes and leukocytes from human and murine blood upon treatment with gadolinium-based contrast agents for magnetic resonance imaging. Invest Radiol 55: 30-37. doi: 10.1097/RLI.0000000000000608
    [120] Di Gregorio E, Ferrauto G, Furlan C, et al. (2018) The issue of gadolinium retained in tissue. Invest Radiol 53: 167-172. doi: 10.1097/RLI.0000000000000423
    [121] Kartamihardja AAP, Hanaoka H, Andriana P, et al. (2019) Quantitative analysis of Gd in the protein content of the brain following single injection of gadolinium-based contrast agents (GBCAs) by size exclusion chromatography. Br J Radiol 92: 20190062. doi: 10.1259/bjr.20190062
    [122] Newton BB, Jimenez SA (2009) Mechanism of NSF: New evidence challenging the prevailing theory. J Magn Reson Imaging 30: 1277-1283. doi: 10.1002/jmri.21980
    [123] Taoka T, Jost G, Frenzel T, et al. (2018) Impact of the glymphatic system on the kinetic and distribution of gadodiamide in rat brain. Invest Radiol 53: 529-534. doi: 10.1097/RLI.0000000000000473
    [124] Nehra AK, McDonald RJ, Bluhm AM, et al. (2018) Accumulation of gadolinium in human cerebrospinal fluid after gadobutrol-enhanced MR imaging: a prospective observational cohort study. Radiology 288: 416-423. doi: 10.1148/radiol.2018171105
    [125] McDonald RJ, Levine D, Weinreb J, et al. (2018) Gadolinium retention: A research roadmap from the 2018 NIH/ACR/RSNA workshop on gadolinium chelates. Radiology 289: 517-534. doi: 10.1148/radiol.2018181151
    [126] Le Fur M, Caravan P (2019) The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists. Metallomics 11: 240-254. doi: 10.1039/C8MT00302E
    [127] Tweedle MF (2016) Gadolinium deposition: Is it chelated or dissociated gadolinium? How can we tell? Magn Res Imaging 34: 1377-1382. doi: 10.1016/j.mri.2016.09.003
    [128] Kiviniemi A, Gardberg M, Ek P, et al. (2019) Gadolinium retention in gliomas and adjacent normal brain tissue: association with tumor contrast enhancement and linear/macrocyclic agents. Neuroradiology 61: 535-544. doi: 10.1007/s00234-019-02172-6
    [129] Kanda T, Fukusato T, Matsuda M, et al. (2015) Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 276: 228-232. doi: 10.1148/radiol.2015142690
    [130] Herculano-Houzel S (2009) The human brain in numbers: a linearly scaled-up primate brain. Front Hum Neurosci 3: 31. doi: 10.3389/neuro.09.031.2009
    [131] Popescu BFG, Robinson CA, Rajput A, et al. (2009) Iron, copper, and zinc distribution of the cerebellum. Cerebellum 8: 74-79. doi: 10.1007/s12311-008-0091-3
    [132] Kromrey ML, Liedtke KR, Ittermann T, et al. (2017) Intravenous injection of gadobutrol in an epidemiological study group did not lead to a difference in relative signal intensities of certain brain structures after 5years. Eur Radiol 27: 772-777. doi: 10.1007/s00330-016-4418-z
    [133] Staks T, Schuhmann-Giampieri G, Frenzel T, et al. (1994) Pharmacokinetics, dose proportionality and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol 29: 709-715. doi: 10.1097/00004424-199407000-00008
    [134] Gutierrez JE, Rosenberg M, Duhaney M, et al. (2015) Phase 3 efficacy and safety trial of gadobutrol, a 1.0 molar macrocyclic MR imaging contrast agent, in patients referred for contrast-enhanced MR imagingof the central nervous system. J Magn Reson Imaging 41: 788-796. doi: 10.1002/jmri.24583
    [135] Kuwatsuru R, Takahashi S, Umeoka S, et al. (2015) A multicenter, randomized, controlled, single-blind comparison phase III study to determine the efficacy and safety of gadobutrol 1.0 M versus gadopentetate dimeglumine following single injection in patients referred for contrast-enhanced MRI of the body regions or extremities. J Magn Reson Imaging 41: 404-413. doi: 10.1002/jmri.24566
    [136] Liang Z, Ma L, Wang D, et al. (2012) Efficacy and safety of gadobutrol (1.0 M) versus gadopentetate dimeglumine (0.5 M) for enhanced MRI of CNS lesions: A phase III, multicenter, single-blind, randomized study in Chinese patients. Mag Res Insights 5: MRI-S9348.
    [137] Naito S, Tazaki H, Okamoto T, et al. (2017) Comparison of nephrotoxicity between two gadolinium-contrasts, gadodiamide and gadopentetate in patients with mildly diminished renal failure. J Toxicol Sci 42: 379-384. doi: 10.2131/jts.42.379
    [138] Semelka RC, Hernandes MA, Stallings CG, et al. (2013) Objective evaluation of acute adverse events andimage quality of gadolinium-based contrast agents (gadobutrol and gadobenate dimeglumine) by blinded evaluation. Pilot study. Magn Reson Imaging 31: 96-101. doi: 10.1016/j.mri.2012.06.025
    [139] Tanaka A, Masumoto T, Yamada H, et al. (2016) A Japanese, multicenter, open-label, phase 3 study to investigate the safety and efficacy of gadobutrol for contrast-enhanced MR imaging of the central nervous system. Magn Reson Med Sci 15: 227-236. doi: 10.2463/mrms.mp.2015-0083
    [140] Zech CJ, Schwenke C, Endrikat J (2019) Diagnostic efficacy and safety of gadoxetate disodium vs gadobenate dimeglumine in patients with known or suspected focal liver lesions: Results of a clinical phase III study. Magn Reson Insight 12: 1178623X19827976.
    [141] Tweedle MF, Wedeking P, Kumar K (1995) Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 30: 372-380. doi: 10.1097/00004424-199506000-00008
    [142] Rocklage SM, Worah D, Kim SH (1991) Metal ion release from paramagnetic chelates: what is tolerable? Magn Reson Med 22: 216-221. doi: 10.1002/mrm.1910220211
    [143] Khairinisa MA, Takatsuru Y, Amano I, et al. (2018) The effect of perinatal gadolinium-based contrast agents. Invest Radiol 53: 110-118. doi: 10.1097/RLI.0000000000000417
    [144] Ray JG, Vermeulen MJ, Bharatha A, et al. (2016) Association between MRI exposure during pregnancy and fetal and childhood outcomes. JAMA 316: 952-961. doi: 10.1001/jama.2016.12126
    [145] Runge VM, Kuehl TJ, Jackson CB, et al. (2005) Subchronic toxicity of the gadolinium chelates. Acad Radiol 12: S6-S9. doi: 10.1016/j.acra.2005.02.015
    [146] Alkhunizi SM, Fakhoury M, Abou-Kheir W, et al. (2020) Gadolinium retention in the central and peripheral nervous system: implications for pain, cognition, and neurogenesis. Radiology 297: 407-416. doi: 10.1148/radiol.2020192645
    [147] Wang S, Hesse B, Roman M, et al. (2019) Increased retention of gadolinium in the inflamed brain after repeated administration of gadopentetate dimeglumine. Invest Radiol 54: 617-626. doi: 10.1097/RLI.0000000000000571
    [148] Reimer P, Vosshenrich R (2008) Off-label use of contrast agents. Eur Radiol 18: 1096-1101. doi: 10.1007/s00330-008-0886-0
    [149] Essig M, Shiroishi MS, Nguyen TB, et al. (2013) Perfusion MRI: The five most frequently asked technical questions. Am J Roentgenol 200: 24-34. doi: 10.2214/AJR.12.9543
    [150] Wolansky LJ, Cadavid D, Punia V, et al. (2015) Hypophosphatemia is associated with the serial administration of triple-dose gadolinium to patients for brain MRI. J Neuroimaging 25: 379-383. doi: 10.1111/jon.12241
    [151] Essig M, Giesel E, Le-Huu M, et al. (2004) Perfusion MRI in CNS disease: current concepts. Neuroradiology 46: S201-S207. doi: 10.1007/s00234-004-1331-y
    [152] Lee JY, Park JE, Kim HS, et al. (2017) Up to 52 administrations of macrocyclic ionic MR contrast agent are not associated with intracranial gadolinium deposition: multifactorial analysis in 385 patients. PloS One 12: e0183916. doi: 10.1371/journal.pone.0183916
    [153] Ng KH, Ahmad AC, Nizam M, et al.Magnetic resonance imaging: Health effects and safety, Proceedings of the international conference on non-ionizing radiation at UNITEN, Electromagnetic Fields and our Health. (2003) .
    [154] Cho S, Lee Y, Choi YJ, et al. (2014) Enhanced cytotoxic and genotoxic effects of gadolinium following ELF-EMF irradiation in human lymphocytes. Drug Chem Toxicol 37: 440-447. doi: 10.3109/01480545.2013.879662
    [155] Sadiq S, Ghazala Z, Chowdhury A, et al. (2012) Metal toxicity at the synapse: presynaptic, postsynaptic, and long-term effects. J Toxicol 2012: 132671. doi: 10.1155/2012/132671
    [156]  Food U S, Drug Administration, Safety Announcement 2017 Available from: https://www.fda.gov/media/109825/download.
    [157] Veiga M, Mattiazzi P, de Goisc JS, et al. (2020) Presence of other rare earth metals in gadolinium-based contrast agents. Talanta 216: 120940. doi: 10.1016/j.talanta.2020.120940
    [158] Parfrey P (2005) The clinical epidemiology of contrast-induced nephropathy. Cardiovasc Intervent Radiol 28: S3-S11. doi: 10.1007/s00270-005-0196-8
    [159] Karcaaltincaba M, Oguz B, Haliloglu M (2009) Current status of contrast-induced nephropathy and nephrogenic systemic fibrosis in children. Pediatr Radiol 39: S382-S384. doi: 10.1007/s00247-009-1236-3
    [160] Kulaksiz S, Bau M (2011) Anthropogenic gadolinium as a micro-contaminant in tap water used as drinking water in urban areas and megacities. Appl Geochem 26: 1877-1885. doi: 10.1016/j.apgeochem.2011.06.011
    [161] Hatje V, Bruland KW, Flegal AR (2016) Increases in anthropogenic gadolinium anomalies and rare earth element concentrations in San Francisco bay over a 20 year record. Environ Sci Technol 50: 4159-4168. doi: 10.1021/acs.est.5b04322
    [162] Rabiet M, Brissaud F, Seidel JL, et al. (2009) Positive gadolinium anomalies in wastewater treatment plant effluents and aquatic environment in the Hérault watershed (South France). Chemosphere 75: 1057-1064. doi: 10.1016/j.chemosphere.2009.01.036
    [163] Chen Y, Cao XD, Lu Y, et al. (2000) Effects of rare earth metal ions and their EDTA complexes on antioxidant enzymes of fish liver. B Environ Contam Tox 65: 357-365. doi: 10.1007/s001280000136
    [164] Henriques B, Coppola F, Monteiro R, et al. (2019) Toxicological assessment of anthropogenic gadolinium in seawater: Biochemical effects in mussels mytilus galloprovincialis. Sci Total Environ 664: 626-634. doi: 10.1016/j.scitotenv.2019.01.341
    [165] Hanana H, Turcotte P, André C, et al. (2017) Comparative study of the effects of gadolinium chloride and gadolinium-based magnetic resonance imaging contrast agent on freshwater mussel, dreissena polymorphaChemosphere 181: 197-207. doi: 10.1016/j.chemosphere.2017.04.073
    [166] Martino C, Costa C, Roccheria MC, et al. (2018) Gadolinium perturbs expression of skeletogenic genes, calcium uptake and larval development in phylogenetically distant sea urchin species. Aquat Toxicol 194: 57-66. doi: 10.1016/j.aquatox.2017.11.004
    [167] Schmidt K, Bau M, Merschel G, et al. (2019) Anthropogenic gadolinium in tap water and in tap-based beverages from fast-food franchises in six major cities in Germany. Sci Total Environ 687: 1401-1408. doi: 10.1016/j.scitotenv.2019.07.075
  • This article has been cited by:

    1. Fethi Souna, Salih Djilali, Abdelkader Lakmeche, Spatiotemporal behavior in a predator–prey model with herd behavior and cross-diffusion and fear effect, 2021, 136, 2190-5444, 10.1140/epjp/s13360-021-01489-7
    2. Jiao-Guo Wang, Xin-You Meng, Long Lv, Jie Li, Stability and Bifurcation Analysis of a Beddington–DeAngelis Prey–Predator Model with Fear Effect, Prey Refuge and Harvesting, 2023, 33, 0218-1274, 10.1142/S021812742350013X
    3. Ankur Jyoti Kashyap, Debasish Bhattacharjee, Hemanta Kumar Sarmah, A fractional model in exploring the role of fear in mass mortality of pelicans in the Salton Sea, 2021, 11, 2146-5703, 28, 10.11121/ijocta.2021.1123
    4. Chuangliang Qin, Jinji Du, Yuanxian Hui, Dynamical behavior of a stochastic predator-prey model with Holling-type III functional response and infectious predator, 2022, 7, 2473-6988, 7403, 10.3934/math.2022413
    5. Juan Liu, Tareq Saeed, Anwar Zeb, Delay effect of an e-epidemic SEIRS malware propagation model with a generalized non-monotone incidence rate, 2022, 39, 22113797, 105672, 10.1016/j.rinp.2022.105672
    6. Aihua Duan, Jian Ke, Dynamics of a delayed model for the propagation of smartphone virus, 2022, 40, 22113797, 105852, 10.1016/j.rinp.2022.105852
    7. M. Priyanka, P. Muthukumar, Sachin Bhalekar, Stability and Bifurcation Analysis of Two-Species Prey–Predator Model Incorporating External Factors, 2022, 32, 0218-1274, 10.1142/S0218127422501723
    8. Muhammad Shoaib Arif, Kamaleldin Abodayeh, Asad Ejaz, On the stability of the diffusive and non-diffusive predator-prey system with consuming resources and disease in prey species, 2023, 20, 1551-0018, 5066, 10.3934/mbe.2023235
    9. Qamar Din, Muhammad Arfan Zulfiqar, Qualitative behavior of a discrete predator–prey system under fear effects, 2022, 77, 0932-0784, 1023, 10.1515/zna-2022-0129
    10. Jia Liu, Yongli Cai, Jing Tan, Yeqin Chen, Dynamical behaviours of a delayed diffusive eco-epidemiological model with fear effect, 2022, 161, 09600779, 112349, 10.1016/j.chaos.2022.112349
    11. Ashvini Gupta, Balram Dubey, Bifurcation and chaos in a delayed eco-epidemic model induced by prey configuration, 2022, 165, 09600779, 112785, 10.1016/j.chaos.2022.112785
    12. San-Xing Wu, Zhi-Cheng Wang, Shigui Ruan, Hopf bifurcation in an age-structured predator–prey system with Beddington–DeAngelis functional response and constant harvesting, 2024, 88, 0303-6812, 10.1007/s00285-024-02070-3
    13. Debashis Das, Sarbani Chakraborty, A brief discussion about a predator-prey model including disease in predators with the delay effect, 2023, 0, 2155-3289, 0, 10.3934/naco.2023018
    14. Ziwei Liang, Xinyou Meng, Stability and Hopf bifurcation of a multiple delayed predator–prey system with fear effect, prey refuge and Crowley–Martin function, 2023, 175, 09600779, 113955, 10.1016/j.chaos.2023.113955
    15. Yujie Cai, Qiaoling Chen, Zhidong Teng, Ge Zhang, Ramziya Rifhat, Bifurcations in a discrete-time Beddington–DeAngelis prey–predator model with fear effect, prey refuge and harvesting, 2024, 0924-090X, 10.1007/s11071-024-10232-7
    16. Aneesh Panchal, Kirti Beniwal, Vivek Kumar, Predator Prey Scavenger Model using Holling’s Functional Response of Type III and Physics-Informed Deep Neural Networks, 2025, 11, 2349-5103, 10.1007/s40819-025-01862-5
    17. Roaa Hatem Talib, Raid Kamel Naji, Chong Lin, The Effect of Fear and Refuge on the Dynamics of a Predator–Prey Model Incorporating Disease in Predator, 2025, 2025, 1110-757X, 10.1155/jama/8120929
  • Reader Comments
  • © 2021 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(10448) PDF downloads(487) Cited by(7)

Figures and Tables

Tables(1)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog